WO2022100738A1 - 含二并环类衍生物抑制剂自由碱的晶型及其制备方法和应用 - Google Patents
含二并环类衍生物抑制剂自由碱的晶型及其制备方法和应用 Download PDFInfo
- Publication number
- WO2022100738A1 WO2022100738A1 PCT/CN2021/130725 CN2021130725W WO2022100738A1 WO 2022100738 A1 WO2022100738 A1 WO 2022100738A1 CN 2021130725 W CN2021130725 W CN 2021130725W WO 2022100738 A1 WO2022100738 A1 WO 2022100738A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- diffraction
- methyl
- pyridin
- pyridine
- diffraction peaks
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 137
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 239000012458 free base Substances 0.000 title claims abstract description 21
- 239000003112 inhibitor Substances 0.000 title claims abstract description 8
- 125000002619 bicyclic group Chemical group 0.000 title abstract description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 134
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 37
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 147
- -1 nitro, hydroxyl Chemical group 0.000 claims description 143
- QHYZFTNTVXUBOP-UHFFFAOYSA-N pyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound C1=CC=CC2=C(C#N)C=NN21 QHYZFTNTVXUBOP-UHFFFAOYSA-N 0.000 claims description 102
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 95
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 87
- 125000000217 alkyl group Chemical group 0.000 claims description 86
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 81
- 239000007787 solid Substances 0.000 claims description 80
- 125000003545 alkoxy group Chemical group 0.000 claims description 68
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 57
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 52
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 49
- 229910052805 deuterium Inorganic materials 0.000 claims description 45
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 44
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 44
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 43
- 125000000623 heterocyclic group Chemical group 0.000 claims description 41
- 229910052736 halogen Inorganic materials 0.000 claims description 38
- 150000002367 halogens Chemical group 0.000 claims description 38
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 37
- 229910052739 hydrogen Inorganic materials 0.000 claims description 37
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 36
- 150000002431 hydrogen Chemical group 0.000 claims description 36
- 239000001257 hydrogen Substances 0.000 claims description 36
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 33
- 239000002904 solvent Substances 0.000 claims description 33
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 32
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 30
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 29
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 28
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 27
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 27
- 229910052757 nitrogen Inorganic materials 0.000 claims description 27
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 24
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 24
- 125000001072 heteroaryl group Chemical group 0.000 claims description 24
- 239000000047 product Substances 0.000 claims description 23
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 20
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 20
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims description 20
- 125000001424 substituent group Chemical group 0.000 claims description 20
- 229910020008 S(O) Inorganic materials 0.000 claims description 19
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 18
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 18
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 18
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 17
- 239000000725 suspension Substances 0.000 claims description 17
- 125000003342 alkenyl group Chemical group 0.000 claims description 16
- 125000000304 alkynyl group Chemical group 0.000 claims description 16
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 16
- 125000003118 aryl group Chemical group 0.000 claims description 15
- 239000000460 chlorine Substances 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 14
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 13
- 239000006228 supernatant Substances 0.000 claims description 13
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 12
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 12
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 12
- 239000002585 base Substances 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 12
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 claims description 12
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 claims description 12
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 claims description 11
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 11
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 11
- 229910052801 chlorine Inorganic materials 0.000 claims description 11
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 11
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 10
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 10
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 9
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Chemical group C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 9
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 9
- 229910052731 fluorine Inorganic materials 0.000 claims description 9
- 239000011737 fluorine Substances 0.000 claims description 9
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 9
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 9
- 125000003566 oxetanyl group Chemical group 0.000 claims description 9
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 8
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 claims description 8
- 229960004592 isopropanol Drugs 0.000 claims description 8
- 229940011051 isopropyl acetate Drugs 0.000 claims description 8
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims description 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 6
- 125000002393 azetidinyl group Chemical group 0.000 claims description 6
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 6
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 claims description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 5
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 5
- 229910052794 bromium Inorganic materials 0.000 claims description 5
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 125000004043 oxo group Chemical group O=* 0.000 claims description 5
- 125000003386 piperidinyl group Chemical group 0.000 claims description 5
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims description 4
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 4
- 125000001188 haloalkyl group Chemical group 0.000 claims description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 4
- 229920002554 vinyl polymer Polymers 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 208000037196 Medullary thyroid carcinoma Diseases 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 125000005842 heteroatom Chemical group 0.000 claims description 3
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 3
- 125000002053 thietanyl group Chemical group 0.000 claims description 3
- 208000013818 thyroid gland medullary carcinoma Diseases 0.000 claims description 3
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 150000001350 alkyl halides Chemical class 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 238000002425 crystallisation Methods 0.000 claims description 2
- 230000008025 crystallization Effects 0.000 claims description 2
- CPPKAGUPTKIMNP-UHFFFAOYSA-N cyanogen fluoride Chemical group FC#N CPPKAGUPTKIMNP-UHFFFAOYSA-N 0.000 claims description 2
- 125000001841 imino group Chemical group [H]N=* 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 2
- 208000013076 thyroid tumor Diseases 0.000 claims description 2
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000030507 AIDS Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 239000002994 raw material Substances 0.000 description 96
- 238000005481 NMR spectroscopy Methods 0.000 description 69
- 210000004027 cell Anatomy 0.000 description 62
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 56
- 239000000243 solution Substances 0.000 description 56
- 238000006243 chemical reaction Methods 0.000 description 53
- 235000019439 ethyl acetate Nutrition 0.000 description 44
- 238000012360 testing method Methods 0.000 description 39
- 238000002474 experimental method Methods 0.000 description 37
- 239000012074 organic phase Substances 0.000 description 34
- 239000012043 crude product Substances 0.000 description 27
- 238000004440 column chromatography Methods 0.000 description 23
- 230000000694 effects Effects 0.000 description 22
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 22
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 21
- 239000000203 mixture Substances 0.000 description 20
- WNPSOODWDSNATA-DPHZAUTASA-N C[C@](COC1=CN2C(=C(C=N2)C#N)C(=C1)C3=CN=C(C=C3)N4CC5CC(C4)N5CC6=CN=C(C=C6)OC)(C#C)O Chemical compound C[C@](COC1=CN2C(=C(C=N2)C#N)C(=C1)C3=CN=C(C=C3)N4CC5CC(C4)N5CC6=CN=C(C=C6)OC)(C#C)O WNPSOODWDSNATA-DPHZAUTASA-N 0.000 description 19
- 230000005764 inhibitory process Effects 0.000 description 17
- 230000002401 inhibitory effect Effects 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- AHPHVOOWKHXBEY-UHFFFAOYSA-N 6-bromo-4-[6-[6-[(6-methoxypyridin-3-yl)methyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]pyridin-3-yl]pyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound COC1=NC=C(CN2C3CC2CN(C3)C2=CC=C(C=N2)C2=CC(Br)=CN3N=CC(C#N)=C23)C=C1 AHPHVOOWKHXBEY-UHFFFAOYSA-N 0.000 description 14
- 239000003153 chemical reaction reagent Substances 0.000 description 14
- DKFSHEGEYOYPSW-UHFFFAOYSA-N 6-hydroxy-4-[6-[6-[(6-methoxypyridin-3-yl)methyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]pyridin-3-yl]pyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound OC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC DKFSHEGEYOYPSW-UHFFFAOYSA-N 0.000 description 13
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 12
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 11
- 238000001514 detection method Methods 0.000 description 11
- 238000010586 diagram Methods 0.000 description 11
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 10
- XPZNKHYKTJJRPZ-UHFFFAOYSA-N COC1=C(C=C(C=N1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)Br)F Chemical compound COC1=C(C=C(C=N1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)Br)F XPZNKHYKTJJRPZ-UHFFFAOYSA-N 0.000 description 10
- 108091000080 Phosphotransferase Proteins 0.000 description 10
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 10
- 239000003513 alkali Substances 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 125000000753 cycloalkyl group Chemical group 0.000 description 10
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 10
- 238000000605 extraction Methods 0.000 description 10
- 239000012091 fetal bovine serum Substances 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 230000026731 phosphorylation Effects 0.000 description 10
- 238000006366 phosphorylation reaction Methods 0.000 description 10
- 102000020233 phosphotransferase Human genes 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 9
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- 238000012216 screening Methods 0.000 description 9
- RUNGVBUEUOEYIF-UHFFFAOYSA-N COC1=C(C=C(C=N1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)O)F Chemical compound COC1=C(C=C(C=N1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)O)F RUNGVBUEUOEYIF-UHFFFAOYSA-N 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 238000001291 vacuum drying Methods 0.000 description 8
- RKKSEJRCJXFWOO-UHFFFAOYSA-N (6-bromo-3-cyanopyrazolo[1,5-a]pyridin-4-yl) trifluoromethanesulfonate Chemical compound FC(F)(F)S(=O)(=O)OC1=CC(Br)=CN2N=CC(C#N)=C12 RKKSEJRCJXFWOO-UHFFFAOYSA-N 0.000 description 7
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 7
- 229910000024 caesium carbonate Inorganic materials 0.000 description 7
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 description 7
- 238000002953 preparative HPLC Methods 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- CEBKHWWANWSNTI-UHFFFAOYSA-N 2-methylbut-3-yn-2-ol Chemical compound CC(C)(O)C#C CEBKHWWANWSNTI-UHFFFAOYSA-N 0.000 description 6
- UYWZRBUFZICZCU-UHFFFAOYSA-N 4-bromo-6-hydroxypyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound BrC=1C=2N(C=C(C=1)O)N=CC=2C#N UYWZRBUFZICZCU-UHFFFAOYSA-N 0.000 description 6
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 description 6
- LJTVFKYAYSGFOV-UHFFFAOYSA-N C1C2CN(CC1N2)C3=NC=C(C=C3)C4=CC(=CN5C4=C(C=N5)C#N)Br Chemical compound C1C2CN(CC1N2)C3=NC=C(C=C3)C4=CC(=CN5C4=C(C=N5)C#N)Br LJTVFKYAYSGFOV-UHFFFAOYSA-N 0.000 description 6
- TXPPYKRMIRGUFD-UHFFFAOYSA-N CC(=O)COC1=CN2C(=C(C=N2)C#N)C(=C1)C3=CN=C(C=C3)N4CC5CC(C4)N5CC6=CN=C(C=C6)OC Chemical compound CC(=O)COC1=CN2C(=C(C=N2)C#N)C(=C1)C3=CN=C(C=C3)N4CC5CC(C4)N5CC6=CN=C(C=C6)OC TXPPYKRMIRGUFD-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- AHPHVOOWKHXBEY-FIBGUPNXSA-N [2H]C([2H])([2H])OC1=NC=C(C=C1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)Br Chemical compound [2H]C([2H])([2H])OC1=NC=C(C=C1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)Br AHPHVOOWKHXBEY-FIBGUPNXSA-N 0.000 description 6
- 235000019270 ammonium chloride Nutrition 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- 238000010791 quenching Methods 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 5
- IWTFOFMTUOBLHG-UHFFFAOYSA-N 2-methoxypyridine Chemical compound COC1=CC=CC=N1 IWTFOFMTUOBLHG-UHFFFAOYSA-N 0.000 description 5
- 241000699660 Mus musculus Species 0.000 description 5
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical class [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 5
- 238000002441 X-ray diffraction Methods 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 238000010009 beating Methods 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- VUQUOGPMUUJORT-UHFFFAOYSA-N methyl 4-methylbenzenesulfonate Chemical compound COS(=O)(=O)C1=CC=C(C)C=C1 VUQUOGPMUUJORT-UHFFFAOYSA-N 0.000 description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 5
- 238000011580 nude mouse model Methods 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 238000003672 processing method Methods 0.000 description 5
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- 125000006413 ring segment Chemical group 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- ZIGSROJSFJRBBT-UHFFFAOYSA-N (1-cyanocyclopropyl)methyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCC1(C#N)CC1 ZIGSROJSFJRBBT-UHFFFAOYSA-N 0.000 description 4
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 4
- VUGCBIWQHSRQBZ-UHFFFAOYSA-N 2-methylbut-3-yn-2-amine Chemical compound CC(C)(N)C#C VUGCBIWQHSRQBZ-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- XSMKXVGNAKMLEQ-UHFFFAOYSA-N 6-bromo-4-(6-fluoropyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound FC1=CC=C(C=N1)C1=CC(Br)=CN2N=CC(C#N)=C12 XSMKXVGNAKMLEQ-UHFFFAOYSA-N 0.000 description 4
- CJLHTKGWEUGORV-UHFFFAOYSA-N Artemin Chemical compound C1CC2(C)C(O)CCC(=C)C2(O)C2C1C(C)C(=O)O2 CJLHTKGWEUGORV-UHFFFAOYSA-N 0.000 description 4
- VXBMJIBCBZMEEL-UHFFFAOYSA-N COC1=NC=C(C=C1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)N Chemical compound COC1=NC=C(C=C1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)N VXBMJIBCBZMEEL-UHFFFAOYSA-N 0.000 description 4
- YXTDEXZRASXXNZ-UHFFFAOYSA-N ClCc1ccc(OC2CC2)nc1 Chemical compound ClCc1ccc(OC2CC2)nc1 YXTDEXZRASXXNZ-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- DKFSHEGEYOYPSW-FIBGUPNXSA-N [2H]C([2H])([2H])OC1=NC=C(C=C1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)O Chemical compound [2H]C([2H])([2H])OC1=NC=C(C=C1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)O DKFSHEGEYOYPSW-FIBGUPNXSA-N 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 125000003282 alkyl amino group Chemical group 0.000 description 4
- 210000003050 axon Anatomy 0.000 description 4
- VQFAIAKCILWQPZ-UHFFFAOYSA-N bromoacetone Chemical compound CC(=O)CBr VQFAIAKCILWQPZ-UHFFFAOYSA-N 0.000 description 4
- 238000012054 celltiter-glo Methods 0.000 description 4
- 125000000000 cycloalkoxy group Chemical group 0.000 description 4
- 125000005366 cycloalkylthio group Chemical group 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 230000007783 downstream signaling Effects 0.000 description 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 4
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- ALDIUUDTUYLMIV-UHFFFAOYSA-N 2-(azetidin-3-yl)propan-2-ol Chemical compound CC(C)(O)C1CNC1 ALDIUUDTUYLMIV-UHFFFAOYSA-N 0.000 description 3
- WBBPRCNXBQTYLF-UHFFFAOYSA-N 2-methylthioethanol Chemical compound CSCCO WBBPRCNXBQTYLF-UHFFFAOYSA-N 0.000 description 3
- GASBTFHFDVWFRJ-UHFFFAOYSA-N 3-(5-bromopyridin-2-yl)-3,6-diazabicyclo[3.1.1]heptane Chemical compound BrC1=CC=C(N=C1)N1CC2CC(C1)N2 GASBTFHFDVWFRJ-UHFFFAOYSA-N 0.000 description 3
- UDYPJTPDZBTEQK-UHFFFAOYSA-N 3-(bromomethyl)bicyclo[1.1.1]pentan-1-ol Chemical compound OC12CC(CBr)(C1)C2 UDYPJTPDZBTEQK-UHFFFAOYSA-N 0.000 description 3
- PGWBIWDVACIZAM-UHFFFAOYSA-N 3-bromo-5-(2-methylsulfonylethyl)pyridine Chemical compound CS(=O)(=O)CCC1=CN=CC(Br)=C1 PGWBIWDVACIZAM-UHFFFAOYSA-N 0.000 description 3
- LDLAEUFQUOXALI-UHFFFAOYSA-N 3-methylazetidin-3-ol Chemical compound CC1(O)CNC1 LDLAEUFQUOXALI-UHFFFAOYSA-N 0.000 description 3
- VYFRXIJQTMYYGB-UHFFFAOYSA-N 3-methylazetidine-3-carbonitrile Chemical compound N#CC1(C)CNC1 VYFRXIJQTMYYGB-UHFFFAOYSA-N 0.000 description 3
- GZPHSAQLYPIAIN-UHFFFAOYSA-N 3-pyridinecarbonitrile Chemical compound N#CC1=CC=CN=C1 GZPHSAQLYPIAIN-UHFFFAOYSA-N 0.000 description 3
- ZFXHFHMHEYHPDP-UHFFFAOYSA-N 6-(3-hydroxy-3-methylbut-1-ynyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound CC(C)(C#CC1=CN2N=CC(C#N)=C2C(B2OC(C)(C)C(C)(C)O2)=C1)O ZFXHFHMHEYHPDP-UHFFFAOYSA-N 0.000 description 3
- NJLVCKWNDUOIRQ-UHFFFAOYSA-N 6-bromo-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound CC1(C)OB(C2=CC(Br)=CN3N=CC(C#N)=C23)OC1(C)C NJLVCKWNDUOIRQ-UHFFFAOYSA-N 0.000 description 3
- 238000011729 BALB/c nude mouse Methods 0.000 description 3
- MKQALSIOGIVOJS-UHFFFAOYSA-N CC(C)(C#CC1=CN2C(=C(C=N2)C#N)C(=C1)C3=CN=C(C=C3)N4CC5CC(C4)N5CC6=CC(=C(N=C6)OC)F)O Chemical compound CC(C)(C#CC1=CN2C(=C(C=N2)C#N)C(=C1)C3=CN=C(C=C3)N4CC5CC(C4)N5CC6=CC(=C(N=C6)OC)F)O MKQALSIOGIVOJS-UHFFFAOYSA-N 0.000 description 3
- KUKVAEGBHLWUFR-UHFFFAOYSA-N CC(C)(C#CC1=CN2C(=C(C=N2)C#N)C(=C1)C3=CN=C(C=C3)N4CC5CC(C4)N5CC6=CN=C(C=C6)OC)O Chemical compound CC(C)(C#CC1=CN2C(=C(C=N2)C#N)C(=C1)C3=CN=C(C=C3)N4CC5CC(C4)N5CC6=CN=C(C=C6)OC)O KUKVAEGBHLWUFR-UHFFFAOYSA-N 0.000 description 3
- BVFLHTFLQSDYBC-UHFFFAOYSA-N CC(C)(C#CC1=CN2C(=C(C=N2)C#N)C(=C1)C3=CN=C(C=C3)N4CC5CC(C4)N5CC6=CN=C(C=C6)OC7CC7)O Chemical compound CC(C)(C#CC1=CN2C(=C(C=N2)C#N)C(=C1)C3=CN=C(C=C3)N4CC5CC(C4)N5CC6=CN=C(C=C6)OC7CC7)O BVFLHTFLQSDYBC-UHFFFAOYSA-N 0.000 description 3
- CVFDNDJNWLCCOU-UHFFFAOYSA-N CC(C)(C(=O)NC1=CN2C(=C(C=N2)C#N)C(=C1)C3=CN=C(C=C3)N4CC5CC(C4)N5CC6=CN=C(C=C6)OC)O Chemical compound CC(C)(C(=O)NC1=CN2C(=C(C=N2)C#N)C(=C1)C3=CN=C(C=C3)N4CC5CC(C4)N5CC6=CN=C(C=C6)OC)O CVFDNDJNWLCCOU-UHFFFAOYSA-N 0.000 description 3
- KJAOCKIRQUNKLA-UHFFFAOYSA-N CC(C)(C1CN(C1)C2=CN3C(=C(C=N3)C#N)C(=C2)C4=CN=C(C=C4)N5CC6CC(C5)N6CC7=CC(=C(N=C7)OC)F)O Chemical compound CC(C)(C1CN(C1)C2=CN3C(=C(C=N3)C#N)C(=C2)C4=CN=C(C=C4)N5CC6CC(C5)N6CC7=CC(=C(N=C7)OC)F)O KJAOCKIRQUNKLA-UHFFFAOYSA-N 0.000 description 3
- YEBGHNZRMZZKKL-UHFFFAOYSA-N CC(C)(COC1=CN2C(=C(C=N2)C#N)C(=C1)Br)C#N Chemical compound CC(C)(COC1=CN2C(=C(C=N2)C#N)C(=C1)Br)C#N YEBGHNZRMZZKKL-UHFFFAOYSA-N 0.000 description 3
- PQNQQPORAOFBNB-UHFFFAOYSA-N CC1(CCN(CC1)C2=NC=C(C=C2)C3=CC(=CN4C3=C(C=N4)C#N)Br)N Chemical compound CC1(CCN(CC1)C2=NC=C(C=C2)C3=CC(=CN4C3=C(C=N4)C#N)Br)N PQNQQPORAOFBNB-UHFFFAOYSA-N 0.000 description 3
- DNTFNMQYTJXINO-UHFFFAOYSA-N CC1=CC=C(C=C1)S(=O)(=O)OCC23CC(C2)(C3)CO Chemical compound CC1=CC=C(C=C1)S(=O)(=O)OCC23CC(C2)(C3)CO DNTFNMQYTJXINO-UHFFFAOYSA-N 0.000 description 3
- OLDBXBZMWVUWIO-UHFFFAOYSA-N COC1=C(C=C(C=N1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)OCC7(COC7)C#N)F Chemical compound COC1=C(C=C(C=N1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)OCC7(COC7)C#N)F OLDBXBZMWVUWIO-UHFFFAOYSA-N 0.000 description 3
- UIYRAPWONPLNJB-UHFFFAOYSA-N COC1=NC=C(C=C1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)CCS(=O)(=O)C Chemical compound COC1=NC=C(C=C1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)CCS(=O)(=O)C UIYRAPWONPLNJB-UHFFFAOYSA-N 0.000 description 3
- QFXCRQBLSRKBHL-UHFFFAOYSA-N COC1=NC=C(C=C1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)NC(=O)C7(CC7)C#N Chemical compound COC1=NC=C(C=C1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)NC(=O)C7(CC7)C#N QFXCRQBLSRKBHL-UHFFFAOYSA-N 0.000 description 3
- WADAIIBQAWFJEI-UHFFFAOYSA-N COC1=NC=C(C=C1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)OCCS(=O)(=O)C Chemical compound COC1=NC=C(C=C1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)OCCS(=O)(=O)C WADAIIBQAWFJEI-UHFFFAOYSA-N 0.000 description 3
- FDDPSENFCCGREJ-UHFFFAOYSA-N CSCCOC1=CN2C(=C(C=N2)C#N)C(=C1)Br Chemical compound CSCCOC1=CN2C(=C(C=N2)C#N)C(=C1)Br FDDPSENFCCGREJ-UHFFFAOYSA-N 0.000 description 3
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 3
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 3
- RCPVDWXDXIJPKV-UHFFFAOYSA-N N-[1-[5-(6-bromo-3-cyanopyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl]-4-methylpiperidin-4-yl]-3-(chloromethyl)pyridine-2-carboxamide Chemical compound BrC=1C=C(C=2N(C1)N=CC2C#N)C=2C=CC(=NC2)N2CCC(CC2)(C)NC(=O)C2=NC=CC=C2CCl RCPVDWXDXIJPKV-UHFFFAOYSA-N 0.000 description 3
- CIZXQTAHDIGOTR-UHFFFAOYSA-N N-[1-[5-[3-cyano-6-[(1-cyanocyclopropyl)methoxy]pyrazolo[1,5-a]pyridin-4-yl]pyridin-2-yl]-4-methylpiperidin-4-yl]-3-(fluoromethyl)pyridine-2-carboxamide Chemical compound CC1(CCN(CC1)C2=NC=C(C=C2)C3=CC(=CN4C3=C(C=N4)C#N)OCC5(CC5)C#N)NC(=O)C6=C(C=CC=N6)CF CIZXQTAHDIGOTR-UHFFFAOYSA-N 0.000 description 3
- PMWMNKZKNKTVDI-UHFFFAOYSA-N N-[1-[5-[6-[(1-aminocyclopropyl)methoxy]-3-cyanopyrazolo[1,5-a]pyridin-4-yl]pyridin-2-yl]-4-methylpiperidin-4-yl]-3-(chloromethyl)pyridine-2-carboxamide Chemical compound CC1(CCN(CC1)C2=NC=C(C=C2)C3=CC(=CN4C3=C(C=N4)C#N)OCC5(CC5)N)NC(=O)C6=C(C=CC=N6)CCl PMWMNKZKNKTVDI-UHFFFAOYSA-N 0.000 description 3
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Substances IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 3
- RVDOXZQUZVOUNB-FIBGUPNXSA-N [2H]C([2H])([2H])OC1=NC=C(C=C1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)OCC7(CC7)C#N Chemical compound [2H]C([2H])([2H])OC1=NC=C(C=C1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)OCC7(CC7)C#N RVDOXZQUZVOUNB-FIBGUPNXSA-N 0.000 description 3
- JYAXTAAJBSRXMB-UHFFFAOYSA-N [3-(hydroxymethyl)-1-bicyclo[1.1.1]pentanyl]methanol Chemical compound C1C2(CO)CC1(CO)C2 JYAXTAAJBSRXMB-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 125000004414 alkyl thio group Chemical group 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 239000006286 aqueous extract Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 150000007942 carboxylates Chemical class 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000005754 cellular signaling Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 210000003292 kidney cell Anatomy 0.000 description 3
- 229940124303 multikinase inhibitor Drugs 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 125000003003 spiro group Chemical group 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 229960000351 terfenadine Drugs 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 201000002510 thyroid cancer Diseases 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- GKPOMITUDGXOSB-SCSAIBSYSA-N (2r)-but-3-yn-2-ol Chemical compound C[C@@H](O)C#C GKPOMITUDGXOSB-SCSAIBSYSA-N 0.000 description 2
- MXZYOPVAKCCOJN-UHFFFAOYSA-N 1-ethynylcyclobutan-1-ol Chemical compound C#CC1(O)CCC1 MXZYOPVAKCCOJN-UHFFFAOYSA-N 0.000 description 2
- WRNHEJNZGOVFTG-UHFFFAOYSA-N 1-ethynylcyclopropan-1-amine Chemical compound C#CC1(N)CC1 WRNHEJNZGOVFTG-UHFFFAOYSA-N 0.000 description 2
- JEBUUQLXYVZBJV-UHFFFAOYSA-N 1-methoxy-2-methylbut-3-yn-2-ol Chemical compound COCC(C)(O)C#C JEBUUQLXYVZBJV-UHFFFAOYSA-N 0.000 description 2
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 2
- BWLBGMIXKSTLSX-UHFFFAOYSA-N 2-hydroxyisobutyric acid Chemical compound CC(C)(O)C(O)=O BWLBGMIXKSTLSX-UHFFFAOYSA-N 0.000 description 2
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 2
- 125000005916 2-methylpentyl group Chemical group 0.000 description 2
- ZAZHRJCWMGXICW-UHFFFAOYSA-N 3-(5-bromopyridin-2-yl)-6-[(6-methoxypyridin-3-yl)methyl]-3,6-diazabicyclo[3.1.1]heptane Chemical compound BrC=1C=CC(=NC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC ZAZHRJCWMGXICW-UHFFFAOYSA-N 0.000 description 2
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000005917 3-methylpentyl group Chemical group 0.000 description 2
- VOTPTQNCWJNQGK-UHFFFAOYSA-N 4-(6-fluoropyridin-3-yl)-6-hydroxypyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound OC1=CN2N=CC(C#N)=C2C(=C1)C1=CC=C(F)N=C1 VOTPTQNCWJNQGK-UHFFFAOYSA-N 0.000 description 2
- SWJWVPMUAUALKX-UHFFFAOYSA-N 4-ethynyloxan-4-ol Chemical compound C#CC1(O)CCOCC1 SWJWVPMUAUALKX-UHFFFAOYSA-N 0.000 description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- IXGQZADMIPXYPJ-UHFFFAOYSA-N 6-[(3-cyanooxetan-3-yl)methoxy]-4-[6-[6-[(6-methoxypyridin-3-yl)methyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]pyridin-3-yl]pyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound COC1=NC=C(C=C1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)OCC7(COC7)C#N IXGQZADMIPXYPJ-UHFFFAOYSA-N 0.000 description 2
- IFUVDUFAFVWZOT-UHFFFAOYSA-N 6-bromo-4-hydroxypyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound BrC=1C=C(C=2N(C=1)N=CC=2C#N)O IFUVDUFAFVWZOT-UHFFFAOYSA-N 0.000 description 2
- CTAIEPPAOULMFY-UHFFFAOYSA-N 6-methoxypyridine-3-carbaldehyde Chemical compound COC1=CC=C(C=O)C=N1 CTAIEPPAOULMFY-UHFFFAOYSA-N 0.000 description 2
- DIBKPCOOJLLKDM-UHFFFAOYSA-N 6-methyl-2-azaspiro[3.3]heptan-6-ol Chemical compound C1C(C)(O)CC11CNC1 DIBKPCOOJLLKDM-UHFFFAOYSA-N 0.000 description 2
- 102100026376 Artemin Human genes 0.000 description 2
- 101710205806 Artemin Proteins 0.000 description 2
- FFEWEMUSMQWRBZ-UHFFFAOYSA-N BrC=1C=C(C=2N(C1)N=CC2C#N)C=2C=CC(=NC2)N2CCC(CC2)(C)NC(C2=C(C=CC(=C2)F)C)=O Chemical compound BrC=1C=C(C=2N(C1)N=CC2C#N)C=2C=CC(=NC2)N2CCC(CC2)(C)NC(C2=C(C=CC(=C2)F)C)=O FFEWEMUSMQWRBZ-UHFFFAOYSA-N 0.000 description 2
- OJNFYZKTIUNLIV-UHFFFAOYSA-N BrC=1C=CC(=NC=1)N1CC2N(C(C1)C2)C(=O)OC(C)(C)C Chemical compound BrC=1C=CC(=NC=1)N1CC2N(C(C1)C2)C(=O)OC(C)(C)C OJNFYZKTIUNLIV-UHFFFAOYSA-N 0.000 description 2
- JJPNOLITLOUEAB-UHFFFAOYSA-N C(#N)C1(CC(C1)COC=1C=C(C=2N(C1)N=CC2C#N)C=2C=NC(=CC2)N2CC1N(C(C2)C1)CC=1C=NC(=C(C1)F)OC)C Chemical compound C(#N)C1(CC(C1)COC=1C=C(C=2N(C1)N=CC2C#N)C=2C=NC(=CC2)N2CC1N(C(C2)C1)CC=1C=NC(=C(C1)F)OC)C JJPNOLITLOUEAB-UHFFFAOYSA-N 0.000 description 2
- BTKLDXSSOSSOBK-UHFFFAOYSA-N C(#N)C1(CCOCC1)COC=1C=C(C=2N(C1)N=CC2C#N)C=2C=NC(=CC2)N2CC1N(C(C2)C1)CC=1C=NC(=C(C1)F)OC Chemical compound C(#N)C1(CCOCC1)COC=1C=C(C=2N(C1)N=CC2C#N)C=2C=NC(=CC2)N2CC1N(C(C2)C1)CC=1C=NC(=C(C1)F)OC BTKLDXSSOSSOBK-UHFFFAOYSA-N 0.000 description 2
- OAZVFBPJNXBQOC-UHFFFAOYSA-N C(#N)C12CC(C1)(C2)COC=2C=C(C=1N(C2)N=CC1C#N)C=1C=NC(=CC1)N1CC2N(C(C1)C2)CC=2C=NC(=C(C2)F)OC Chemical compound C(#N)C12CC(C1)(C2)COC=2C=C(C=1N(C2)N=CC1C#N)C=1C=NC(=CC1)N1CC2N(C(C1)C2)CC=2C=NC(=C(C2)F)OC OAZVFBPJNXBQOC-UHFFFAOYSA-N 0.000 description 2
- UXEMCDFWPAWWDD-VPYROQPTSA-N C(OC1=CC=C(C=N1)CN1C2CN(CC1C2)C1=NC=C(C=C1)B1OC(C(O1)(C)C)(C)C)([2H])([2H])[2H] Chemical compound C(OC1=CC=C(C=N1)CN1C2CN(CC1C2)C1=NC=C(C=C1)B1OC(C(O1)(C)C)(C)C)([2H])([2H])[2H] UXEMCDFWPAWWDD-VPYROQPTSA-N 0.000 description 2
- HFRMEIVOPPGFET-UHFFFAOYSA-N C1C(CC1(F)F)(CCl)C#N Chemical compound C1C(CC1(F)F)(CCl)C#N HFRMEIVOPPGFET-UHFFFAOYSA-N 0.000 description 2
- SKIQHKOYBPZJRF-UHFFFAOYSA-N C1CC1OC2=NC=C(C=C2)CN3C4CC3CN(C4)C5=NC=C(C=C5)C6=CC(=CN7C6=C(C=N7)C#N)Br Chemical compound C1CC1OC2=NC=C(C=C2)CN3C4CC3CN(C4)C5=NC=C(C=C5)C6=CC(=CN7C6=C(C=N7)C#N)Br SKIQHKOYBPZJRF-UHFFFAOYSA-N 0.000 description 2
- MVIJROZDUFZNBY-UHFFFAOYSA-N CC(C)(C#CC1=CN2C(=C(C=N2)C#N)C(=C1)C3=CN=C(C=C3)N4CC5CC(C4)N5CC6=CN=C(C=C6)OC)N Chemical compound CC(C)(C#CC1=CN2C(=C(C=N2)C#N)C(=C1)C3=CN=C(C=C3)N4CC5CC(C4)N5CC6=CN=C(C=C6)OC)N MVIJROZDUFZNBY-UHFFFAOYSA-N 0.000 description 2
- NVIMQZMSLNBCLD-UHFFFAOYSA-N CC(C)(C1CN(C1)C2=CN3C(=C(C=N3)C#N)C(=C2)C4=CN=C(C=C4)N5CC6CC(C5)N6CC7=CN=C(C=C7)OC)O Chemical compound CC(C)(C1CN(C1)C2=CN3C(=C(C=N3)C#N)C(=C2)C4=CN=C(C=C4)N5CC6CC(C5)N6CC7=CN=C(C=C7)OC)O NVIMQZMSLNBCLD-UHFFFAOYSA-N 0.000 description 2
- UUZLSYVLWQSZFH-UHFFFAOYSA-N CC(C)(CC#CC1=CN2C(=C(C=N2)C#N)C(=C1)C3=CN=C(C=C3)N4CC5CC(C4)N5CC6=CN=C(C=C6)OC)O Chemical compound CC(C)(CC#CC1=CN2C(=C(C=N2)C#N)C(=C1)C3=CN=C(C=C3)N4CC5CC(C4)N5CC6=CN=C(C=C6)OC)O UUZLSYVLWQSZFH-UHFFFAOYSA-N 0.000 description 2
- GVYQLGFBHHIVJF-UHFFFAOYSA-N CC(C)(COC1=CN2C(=C(C=N2)C#N)C(=C1)C3=CN=C(C=C3)N4CC5CC(C4)N5CC6=CN=C(C=C6)OC)C#N Chemical compound CC(C)(COC1=CN2C(=C(C=N2)C#N)C(=C1)C3=CN=C(C=C3)N4CC5CC(C4)N5CC6=CN=C(C=C6)OC)C#N GVYQLGFBHHIVJF-UHFFFAOYSA-N 0.000 description 2
- IBQZBBXRKAKMAS-UHFFFAOYSA-N CC(COC)(C#CC1=CN2C(=C(C=N2)C#N)C(=C1)C3=CN=C(C=C3)N4CC5CC(C4)N5CC6=CC(=C(N=C6)OC)F)O Chemical compound CC(COC)(C#CC1=CN2C(=C(C=N2)C#N)C(=C1)C3=CN=C(C=C3)N4CC5CC(C4)N5CC6=CC(=C(N=C6)OC)F)O IBQZBBXRKAKMAS-UHFFFAOYSA-N 0.000 description 2
- HZRSBWRZKTYIDA-UHFFFAOYSA-N CC1(CCN(CC1)C2=NC=C(C=C2)C3=CC(=CN4C3=C(C=N4)C#N)N5CC(C5)(C)C#N)NC(=O)C6=C(C=CC=N6)Cl Chemical compound CC1(CCN(CC1)C2=NC=C(C=C2)C3=CC(=CN4C3=C(C=N4)C#N)N5CC(C5)(C)C#N)NC(=O)C6=C(C=CC=N6)Cl HZRSBWRZKTYIDA-UHFFFAOYSA-N 0.000 description 2
- PTJMBXXMSDNWGG-UHFFFAOYSA-N CC1(CN(C1)C2=CN3C(=C(C=N3)C#N)C(=C2)C4=CN=C(C=C4)N5CC6CC(C5)N6CC7=CC(=C(N=C7)OC)F)C#N Chemical compound CC1(CN(C1)C2=CN3C(=C(C=N3)C#N)C(=C2)C4=CN=C(C=C4)N5CC6CC(C5)N6CC7=CC(=C(N=C7)OC)F)C#N PTJMBXXMSDNWGG-UHFFFAOYSA-N 0.000 description 2
- BZWHVXKLVWBJBO-UHFFFAOYSA-N CC1(CN(C1)C2=CN3C(=C(C=N3)C#N)C(=C2)C4=CN=C(C=C4)N5CC6CC(C5)N6CC7=CC(=C(N=C7)OC)F)O Chemical compound CC1(CN(C1)C2=CN3C(=C(C=N3)C#N)C(=C2)C4=CN=C(C=C4)N5CC6CC(C5)N6CC7=CC(=C(N=C7)OC)F)O BZWHVXKLVWBJBO-UHFFFAOYSA-N 0.000 description 2
- YHLCTXOXWBRXDD-UHFFFAOYSA-N CC1=C(C=C(C=C1)F)C(=O)NC2(CCN(CC2)C3=NC=C(C=C3)C4=CC(=CN5C4=C(C=N5)C#N)C#CC(C)(C)N)C Chemical compound CC1=C(C=C(C=C1)F)C(=O)NC2(CCN(CC2)C3=NC=C(C=C3)C4=CC(=CN5C4=C(C=N5)C#N)C#CC(C)(C)N)C YHLCTXOXWBRXDD-UHFFFAOYSA-N 0.000 description 2
- BIHCUEKPSOAFTJ-UHFFFAOYSA-N CC1=C(C=C(C=C1)F)C(=O)NC2(CCN(CC2)C3=NC=C(C=C3)C4=CC(=CN5C4=C(C=N5)C#N)C#CC(C)(C)O)C Chemical compound CC1=C(C=C(C=C1)F)C(=O)NC2(CCN(CC2)C3=NC=C(C=C3)C4=CC(=CN5C4=C(C=N5)C#N)C#CC(C)(C)O)C BIHCUEKPSOAFTJ-UHFFFAOYSA-N 0.000 description 2
- XPWFYQIHIXGNHV-UHFFFAOYSA-N CC1=CC=C(C=C1)S(=O)(=O)OCC12CC(C1)(C2)C#N Chemical compound CC1=CC=C(C=C1)S(=O)(=O)OCC12CC(C1)(C2)C#N XPWFYQIHIXGNHV-UHFFFAOYSA-N 0.000 description 2
- JNBHHZKDFNGQRD-UHFFFAOYSA-N CC1=CC=C(C=C1)S(=O)(=O)OCC1CC(C1)(C)C#N Chemical compound CC1=CC=C(C=C1)S(=O)(=O)OCC1CC(C1)(C)C#N JNBHHZKDFNGQRD-UHFFFAOYSA-N 0.000 description 2
- GWOSDEWYODRFGH-UHFFFAOYSA-N CN(CC1(CC1)O)C2=CN3C(=C(C=N3)C#N)C(=C2)C4=CN=C(C=C4)N5CC6CC(C5)N6CC7=CN=C(C=C7)OC Chemical compound CN(CC1(CC1)O)C2=CN3C(=C(C=N3)C#N)C(=C2)C4=CN=C(C=C4)N5CC6CC(C5)N6CC7=CN=C(C=C7)OC GWOSDEWYODRFGH-UHFFFAOYSA-N 0.000 description 2
- UZMQEPAPCGSNBC-UHFFFAOYSA-N COC1=C(C=C(C=N1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)C#CC7(CCOCC7)O)F Chemical compound COC1=C(C=C(C=N1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)C#CC7(CCOCC7)O)F UZMQEPAPCGSNBC-UHFFFAOYSA-N 0.000 description 2
- QBPGRUXOQGGICM-UHFFFAOYSA-N COC1=C(C=C(C=N1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)C#CC7(COC7)O)F Chemical compound COC1=C(C=C(C=N1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)C#CC7(COC7)O)F QBPGRUXOQGGICM-UHFFFAOYSA-N 0.000 description 2
- UUVYSESFZUTDMF-UHFFFAOYSA-N COC1=CC=C(CN(C(C2)C3)C2CN3C(N=C2)=CC=C2C2=CC(OCCC(CC3)CC[S+]3O)=CN3N=CC(C#N)=C23)C=N1 Chemical compound COC1=CC=C(CN(C(C2)C3)C2CN3C(N=C2)=CC=C2C2=CC(OCCC(CC3)CC[S+]3O)=CN3N=CC(C#N)=C23)C=N1 UUVYSESFZUTDMF-UHFFFAOYSA-N 0.000 description 2
- GZCHKELUHGTPMJ-UHFFFAOYSA-N COC1=NC=C(C=C1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)C#CC(C7CC7)O Chemical compound COC1=NC=C(C=C1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)C#CC(C7CC7)O GZCHKELUHGTPMJ-UHFFFAOYSA-N 0.000 description 2
- YOTHPPTWYHXLFO-UHFFFAOYSA-N COC1=NC=C(C=C1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)C#CC7(CC7)O Chemical compound COC1=NC=C(C=C1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)C#CC7(CC7)O YOTHPPTWYHXLFO-UHFFFAOYSA-N 0.000 description 2
- WQEBPAGRVDZWBR-UHFFFAOYSA-N COC1=NC=C(C=C1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)C#CC7(CCOCC7)O Chemical compound COC1=NC=C(C=C1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)C#CC7(CCOCC7)O WQEBPAGRVDZWBR-UHFFFAOYSA-N 0.000 description 2
- HKGXNFWXWOSPSR-UHFFFAOYSA-N COC1=NC=C(C=C1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)OCC7(CC7)N Chemical compound COC1=NC=C(C=C1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)OCC7(CC7)N HKGXNFWXWOSPSR-UHFFFAOYSA-N 0.000 description 2
- WMJGVTQONLYTDU-UHFFFAOYSA-N COC1=NC=C(C=C1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)OCC78CC(C7)(C8)C#N Chemical compound COC1=NC=C(C=C1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)OCC78CC(C7)(C8)C#N WMJGVTQONLYTDU-UHFFFAOYSA-N 0.000 description 2
- UIPMZDYPSVIAOC-UHFFFAOYSA-N COC1=NC=C(C=C1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)OCC78CC(C7)(C8)CO Chemical compound COC1=NC=C(C=C1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)OCC78CC(C7)(C8)CO UIPMZDYPSVIAOC-UHFFFAOYSA-N 0.000 description 2
- KLIQFXGEHXWEHO-UHFFFAOYSA-N COC1=NC=C(C=C1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)OCC78CC(C7)(C8)O Chemical compound COC1=NC=C(C=C1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)OCC78CC(C7)(C8)O KLIQFXGEHXWEHO-UHFFFAOYSA-N 0.000 description 2
- QOHHDKCIEIBCKS-UHFFFAOYSA-N COC1=NC=C(C=C1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)OCCCS(=O)(=O)C Chemical compound COC1=NC=C(C=C1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)OCCCS(=O)(=O)C QOHHDKCIEIBCKS-UHFFFAOYSA-N 0.000 description 2
- SIIPUKJCQMZONT-UHFFFAOYSA-N CS(=O)(=O)CCC1=CN2C(=C(C=N2)C#N)C(=C1)Br Chemical compound CS(=O)(=O)CCC1=CN2C(=C(C=N2)C#N)C(=C1)Br SIIPUKJCQMZONT-UHFFFAOYSA-N 0.000 description 2
- CIBPZNKEIRMUMN-XTTWBRMDSA-N C[C@@](COC1=CN2C(=C(C=N2)C#N)C(=C1)C3=CN=C(C=C3)N4CC5CC(C4)N5CC6=CC(=C(N=C6)OC)F)(C#C)O Chemical compound C[C@@](COC1=CN2C(=C(C=N2)C#N)C(=C1)C3=CN=C(C=C3)N4CC5CC(C4)N5CC6=CC(=C(N=C6)OC)F)(C#C)O CIBPZNKEIRMUMN-XTTWBRMDSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- BTUGJVLEILMRLM-UHFFFAOYSA-N ClC=1C(=NC=CC1)C(=O)NC1(CCN(CC1)C1=NC=C(C=C1)C=1C=2N(C=C(C1)N1CC(C1)C(C)(C)O)N=CC2C#N)C Chemical compound ClC=1C(=NC=CC1)C(=O)NC1(CCN(CC1)C1=NC=C(C=C1)C=1C=2N(C=C(C1)N1CC(C1)C(C)(C)O)N=CC2C#N)C BTUGJVLEILMRLM-UHFFFAOYSA-N 0.000 description 2
- FEMPWFVNPGSZCA-UHFFFAOYSA-N ClC=1C(=NC=CC1)C(=O)NC1(CCN(CC1)C1=NC=C(C=C1)C=1C=2N(C=C(C1)OCC1(CC1)C#N)N=CC2C#N)C Chemical compound ClC=1C(=NC=CC1)C(=O)NC1(CCN(CC1)C1=NC=C(C=C1)C=1C=2N(C=C(C1)OCC1(CC1)C#N)N=CC2C#N)C FEMPWFVNPGSZCA-UHFFFAOYSA-N 0.000 description 2
- 206010010539 Congenital megacolon Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- FQDVTAVKOCFSJS-UHFFFAOYSA-N FC=1C=C(C=NC1OC)CN1C2CN(CC1C2)C2=CC=C(C=N2)C=2C=1N(C=C(C2)C#CC2(CCC2)O)N=CC1C#N Chemical compound FC=1C=C(C=NC1OC)CN1C2CN(CC1C2)C2=CC=C(C=N2)C=2C=1N(C=C(C2)C#CC2(CCC2)O)N=CC1C#N FQDVTAVKOCFSJS-UHFFFAOYSA-N 0.000 description 2
- XFVQLMVIELUSBT-WZFBRQLOSA-N FC=1C=C(C=NC1OC)CN1C2CN(CC1C2)C2=CC=C(C=N2)C=2C=1N(C=C(C2)C#C[C@@H](C)O)N=CC1C#N Chemical compound FC=1C=C(C=NC1OC)CN1C2CN(CC1C2)C2=CC=C(C=N2)C=2C=1N(C=C(C2)C#C[C@@H](C)O)N=CC1C#N XFVQLMVIELUSBT-WZFBRQLOSA-N 0.000 description 2
- XAUHHBOGNNKFNH-UHFFFAOYSA-N FC=1C=C(C=NC1OC)CN1C2CN(CC1C2)C2=CC=C(C=N2)C=2C=1N(C=C(C2)OCC(C)=O)N=CC1C#N Chemical compound FC=1C=C(C=NC1OC)CN1C2CN(CC1C2)C2=CC=C(C=N2)C=2C=1N(C=C(C2)OCC(C)=O)N=CC1C#N XAUHHBOGNNKFNH-UHFFFAOYSA-N 0.000 description 2
- VRYIMBMYWRNXAR-UHFFFAOYSA-N FC=1C=C(C=NC1OC)CN1C2CN(CC1C2)C2=CC=C(C=N2)C=2C=1N(C=C(C2)OCC23CC(C2)(C3)CO)N=CC1C#N Chemical compound FC=1C=C(C=NC1OC)CN1C2CN(CC1C2)C2=CC=C(C=N2)C=2C=1N(C=C(C2)OCC23CC(C2)(C3)CO)N=CC1C#N VRYIMBMYWRNXAR-UHFFFAOYSA-N 0.000 description 2
- 229910005429 FeSSIF Inorganic materials 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 238000003043 HTRF KinEASE-TK Methods 0.000 description 2
- 208000004592 Hirschsprung disease Diseases 0.000 description 2
- PIXLZPWQUFTFRL-UHFFFAOYSA-N N-[1-[5-[6-(3-amino-3-methylbut-1-ynyl)-3-cyanopyrazolo[1,5-a]pyridin-4-yl]pyridin-2-yl]-4-methylpiperidin-4-yl]-3-(chloromethyl)pyridine-2-carboxamide Chemical compound CC1(CCN(CC1)C2=NC=C(C=C2)C3=CC(=CN4C3=C(C=N4)C#N)C#CC(C)(C)N)NC(=O)C5=C(C=CC=N5)CCl PIXLZPWQUFTFRL-UHFFFAOYSA-N 0.000 description 2
- 102100021584 Neurturin Human genes 0.000 description 2
- 108010015406 Neurturin Proteins 0.000 description 2
- NVIMQZMSLNBCLD-HPRDVNIFSA-N OC(C)(C)C1CN(C1)C=1C=C(C=2N(C1)N=CC2C#N)C=2C=NC(=CC2)N2CC1N(C(C2)C1)CC=1C=NC(=CC1)OC([2H])([2H])[2H] Chemical compound OC(C)(C)C1CN(C1)C=1C=C(C=2N(C1)N=CC2C#N)C=2C=NC(=CC2)N2CC1N(C(C2)C1)CC=1C=NC(=CC1)OC([2H])([2H])[2H] NVIMQZMSLNBCLD-HPRDVNIFSA-N 0.000 description 2
- GRCCNVZFHYNCFN-UHFFFAOYSA-N OC(CCC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C Chemical compound OC(CCC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C GRCCNVZFHYNCFN-UHFFFAOYSA-N 0.000 description 2
- WNPSOODWDSNATA-UHFFFAOYSA-N OC(COC=1C=C(C=2N(C1)N=CC2C#N)C=2C=NC(=CC2)N2CC1N(C(C2)C1)CC=1C=NC(=CC1)OC)(C#C)C Chemical compound OC(COC=1C=C(C=2N(C1)N=CC2C#N)C=2C=NC(=CC2)N2CC1N(C(C2)C1)CC=1C=NC(=CC1)OC)(C#C)C WNPSOODWDSNATA-UHFFFAOYSA-N 0.000 description 2
- MVQAYSXDCGCOIE-UHFFFAOYSA-N OC1(CN(C1)C=1C=C(C=2N(C1)N=CC2C#N)C=2C=NC(=CC2)N2CC1N(C(C2)C1)CC=1C=NC(=CC1)OC)C Chemical compound OC1(CN(C1)C=1C=C(C=2N(C1)N=CC2C#N)C=2C=NC(=CC2)N2CC1N(C(C2)C1)CC=1C=NC(=CC1)OC)C MVQAYSXDCGCOIE-UHFFFAOYSA-N 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 102100036660 Persephin Human genes 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- ZAZHRJCWMGXICW-FIBGUPNXSA-N [2H]C([2H])([2H])OC1=NC=C(C=C1)CN2C3CC2CN(C3)C4=NC=C(C=C4)Br Chemical compound [2H]C([2H])([2H])OC1=NC=C(C=C1)CN2C3CC2CN(C3)C4=NC=C(C=C4)Br ZAZHRJCWMGXICW-FIBGUPNXSA-N 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000012296 anti-solvent Substances 0.000 description 2
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 2
- AWXXNEOTLRMFKW-UHFFFAOYSA-N bicyclo[1.1.1]pentane-3-carboxamide Chemical compound C1C2CC1(C(=O)N)C2 AWXXNEOTLRMFKW-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- JPOXNPPZZKNXOV-UHFFFAOYSA-N bromochloromethane Chemical compound ClCBr JPOXNPPZZKNXOV-UHFFFAOYSA-N 0.000 description 2
- MKUWVMRNQOOSAT-UHFFFAOYSA-N but-3-en-2-ol Chemical compound CC(O)C=C MKUWVMRNQOOSAT-UHFFFAOYSA-N 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 125000005047 dihydroimidazolyl group Chemical group N1(CNC=C1)* 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 238000010812 external standard method Methods 0.000 description 2
- QEWYKACRFQMRMB-UHFFFAOYSA-N fluoroacetic acid Chemical compound OC(=O)CF QEWYKACRFQMRMB-UHFFFAOYSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 108010070453 persephin Proteins 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 2
- 238000004237 preparative chromatography Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000004853 protein function Effects 0.000 description 2
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 102200006308 rs74799832 Human genes 0.000 description 2
- 102200006097 rs79658334 Human genes 0.000 description 2
- 102200006099 rs79658334 Human genes 0.000 description 2
- 238000005185 salting out Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- HUJVYMOIRWLHFB-UHFFFAOYSA-N tert-butyl N-tert-butyl-N-[3-cyano-4-[6-[6-[(6-methoxypyridin-3-yl)methyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]pyridin-3-yl]pyrazolo[1,5-a]pyridin-6-yl]carbamate Chemical compound C(C)(C)(C)OC(N(C=1C=C(C=2N(C1)N=CC2C#N)C=2C=NC(=CC2)N2CC1N(C(C2)C1)CC=1C=NC(=CC1)OC)C(C)(C)C)=O HUJVYMOIRWLHFB-UHFFFAOYSA-N 0.000 description 2
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 2
- QPMLNOXLVGIOPZ-UHFFFAOYSA-N (1-cyanocyclopentyl)methyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCC1(C#N)CCCC1 QPMLNOXLVGIOPZ-UHFFFAOYSA-N 0.000 description 1
- GKPOMITUDGXOSB-BYPYZUCNSA-N (2s)-but-3-yn-2-ol Chemical compound C[C@H](O)C#C GKPOMITUDGXOSB-BYPYZUCNSA-N 0.000 description 1
- BMQDAIUNAGXSKR-UHFFFAOYSA-N (3-hydroxy-2,3-dimethylbutan-2-yl)oxyboronic acid Chemical compound CC(C)(O)C(C)(C)OB(O)O BMQDAIUNAGXSKR-UHFFFAOYSA-N 0.000 description 1
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
- WICRKCABAQJKSY-UHFFFAOYSA-N 1-(aminomethyl)cyclopropane-1-carbonitrile Chemical compound NCC1(C#N)CC1 WICRKCABAQJKSY-UHFFFAOYSA-N 0.000 description 1
- MVLYIQLMFKZWRQ-UHFFFAOYSA-N 1-(methylaminomethyl)cyclopropan-1-ol Chemical compound CNCC1(O)CC1 MVLYIQLMFKZWRQ-UHFFFAOYSA-N 0.000 description 1
- KSJJMSKNZVXAND-UHFFFAOYSA-N 1-cyanocyclopropane-1-carboxylic acid Chemical compound OC(=O)C1(C#N)CC1 KSJJMSKNZVXAND-UHFFFAOYSA-N 0.000 description 1
- QPACLFFIDGQFRT-UHFFFAOYSA-N 1-ethynylcyclopropan-1-ol Chemical compound C#CC1(O)CC1 QPACLFFIDGQFRT-UHFFFAOYSA-N 0.000 description 1
- IGXNOZPWNAUJHL-UHFFFAOYSA-N 1-fluoro-2-(fluoromethyl)but-3-yn-2-ol Chemical compound FCC(O)(CF)C#C IGXNOZPWNAUJHL-UHFFFAOYSA-N 0.000 description 1
- 125000003562 2,2-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003660 2,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003764 2,4-dimethylpentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- JLWVKGJKBUPZKJ-UHFFFAOYSA-N 2-(thian-4-yl)ethanol Chemical compound OCCC1CCSCC1 JLWVKGJKBUPZKJ-UHFFFAOYSA-N 0.000 description 1
- NNWFSRBWMOZDAK-UHFFFAOYSA-N 2-[2-(carboxymethyl)-3-iodophenyl]acetic acid Chemical compound OC(=O)CC1=CC=CC(I)=C1CC(O)=O NNWFSRBWMOZDAK-UHFFFAOYSA-N 0.000 description 1
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 description 1
- IQHSSYROJYPFDV-UHFFFAOYSA-N 2-bromo-1,3-dichloro-5-(trifluoromethyl)benzene Chemical group FC(F)(F)C1=CC(Cl)=C(Br)C(Cl)=C1 IQHSSYROJYPFDV-UHFFFAOYSA-N 0.000 description 1
- OYUNTGBISCIYPW-UHFFFAOYSA-N 2-chloroprop-2-enenitrile Chemical compound ClC(=C)C#N OYUNTGBISCIYPW-UHFFFAOYSA-N 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- BXOJBMSEIGMKSS-UHFFFAOYSA-N 2-methylpent-4-yn-2-ol Chemical compound CC(C)(O)CC#C BXOJBMSEIGMKSS-UHFFFAOYSA-N 0.000 description 1
- RCXLAPBURAMYKG-UHFFFAOYSA-N 3,3-difluorocyclobutane-1-carbonitrile Chemical compound FC1(F)CC(C#N)C1 RCXLAPBURAMYKG-UHFFFAOYSA-N 0.000 description 1
- 125000004336 3,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- JTSNUDSWODMGOC-UHFFFAOYSA-N 3-chloro-N-[1-[5-(3-cyano-6-hydroxypyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl]-4-methylpiperidin-4-yl]pyridine-2-carboxamide Chemical compound CC1(CCN(CC1)C1=NC=C(C=C1)C1=CC(O)=CN2N=CC(C#N)=C12)NC(=O)C1=C(Cl)C=CC=N1 JTSNUDSWODMGOC-UHFFFAOYSA-N 0.000 description 1
- MUAUTKGQLIGJBG-UHFFFAOYSA-N 3-chloro-N-[1-[5-[3-cyano-6-[2-(3-hydroxyoxetan-3-yl)ethynyl]pyrazolo[1,5-a]pyridin-4-yl]pyridin-2-yl]-4-methylpiperidin-4-yl]pyridine-2-carboxamide Chemical compound CC(CC1)(CCN1C(C=C1)=NC=C1C1=CC(C#CC2(COC2)O)=CN2N=CC(C#N)=C12)NC(C1=NC=CC=C1Cl)=O MUAUTKGQLIGJBG-UHFFFAOYSA-N 0.000 description 1
- LVJSMNMXDWKABU-UHFFFAOYSA-N 3-chloro-N-[[1-[5-[3-cyano-6-(3-hydroxy-3-methylbut-1-ynyl)pyrazolo[1,5-a]pyridin-4-yl]pyridin-2-yl]-4-methylpiperidin-4-yl]methyl]pyridine-2-carboxamide Chemical compound CC1(CCN(CC1)C2=NC=C(C=C2)C3=CC(=CN4C3=C(C=N4)C#N)C#CC(C)(C)O)CNC(=O)C5=C(C=CC=N5)Cl LVJSMNMXDWKABU-UHFFFAOYSA-N 0.000 description 1
- 125000004337 3-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- VDKFNBYHNNAJBC-UHFFFAOYSA-N 3-ethynyloxetan-3-ol Chemical compound C#CC1(O)COC1 VDKFNBYHNNAJBC-UHFFFAOYSA-N 0.000 description 1
- WWXFHHXOVMQARV-UHFFFAOYSA-N 3-hydroxy-2,2-dimethylpropanenitrile Chemical compound OCC(C)(C)C#N WWXFHHXOVMQARV-UHFFFAOYSA-N 0.000 description 1
- GJFHHQJYZGSYSR-UHFFFAOYSA-N 3-hydroxy-3-methylcyclobutane-1-carboxylic acid Chemical compound CC1(O)CC(C(O)=O)C1 GJFHHQJYZGSYSR-UHFFFAOYSA-N 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- ILBDVRCFTYQLOE-UHFFFAOYSA-N 3-methylpyrrolidin-3-ol Chemical compound CC1(O)CCNC1 ILBDVRCFTYQLOE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- SUGKKIXWZASGSG-UHFFFAOYSA-N 4-[6-(3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl]-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound C12CN(CC(N1)C2)C1=CC=C(C=N1)C=1C=2N(C=C(C=1)OCC(C)(C)O)N=CC=2C#N SUGKKIXWZASGSG-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- CXBLQEIODBBSQD-UHFFFAOYSA-N 4-methylpiperidin-4-ol Chemical compound CC1(O)CCNCC1 CXBLQEIODBBSQD-UHFFFAOYSA-N 0.000 description 1
- QRXZNFSVRLDKPE-UHFFFAOYSA-N 5-(chloromethyl)-2-fluoropyridine Chemical compound FC1=CC=C(CCl)C=N1 QRXZNFSVRLDKPE-UHFFFAOYSA-N 0.000 description 1
- MYUQKYGWKHTRPG-UHFFFAOYSA-N 5-bromo-2-fluoropyridine Chemical compound FC1=CC=C(Br)C=N1 MYUQKYGWKHTRPG-UHFFFAOYSA-N 0.000 description 1
- JVBLXLBINTYFPR-UHFFFAOYSA-N 5-fluoro-2-methylbenzoic acid Chemical compound CC1=CC=C(F)C=C1C(O)=O JVBLXLBINTYFPR-UHFFFAOYSA-N 0.000 description 1
- BKATVSAQJLGKJC-UHFFFAOYSA-N 5-fluoro-6-methoxypyridine-3-carbaldehyde Chemical compound COC1=NC=C(C=O)C=C1F BKATVSAQJLGKJC-UHFFFAOYSA-N 0.000 description 1
- UENKEXWHDZHERK-UHFFFAOYSA-N 6-(2-methylsulfonylethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound CS(=O)(=O)CCC=1C=C(C=2N(C1)N=CC2C#N)B2OC(C(O2)(C)C)(C)C UENKEXWHDZHERK-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241000349731 Afzelia bipindensis Species 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- NICRMBNKSIPONI-UHFFFAOYSA-N BrC=1C=CC(=NC1)N1CCC(CC1)(C)NC(C1=C(C=CC(=C1)F)C)=O Chemical compound BrC=1C=CC(=NC1)N1CCC(CC1)(C)NC(C1=C(C=CC(=C1)F)C)=O NICRMBNKSIPONI-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 210000003771 C cell Anatomy 0.000 description 1
- FWSVJIWKFLYGDY-UHFFFAOYSA-N C(#N)C1(CC(C1)(F)F)COC=1C=C(C=2N(C1)N=CC2C#N)C=2C=NC(=CC2)N2CC1N(C(C2)C1)CC=1C=NC(=CC1)OC Chemical compound C(#N)C1(CC(C1)(F)F)COC=1C=C(C=2N(C1)N=CC2C#N)C=2C=NC(=CC2)N2CC1N(C(C2)C1)CC=1C=NC(=CC1)OC FWSVJIWKFLYGDY-UHFFFAOYSA-N 0.000 description 1
- SIEOBYUNQLKWSW-UHFFFAOYSA-N C(#N)C1(CC(C1)COC=1C=C(C=2N(C1)N=CC2C#N)C=2C=NC(=CC2)N2CC1N(C(C2)C1)CC=1C=NC(=CC1)OC)C Chemical compound C(#N)C1(CC(C1)COC=1C=C(C=2N(C1)N=CC2C#N)C=2C=NC(=CC2)N2CC1N(C(C2)C1)CC=1C=NC(=CC1)OC)C SIEOBYUNQLKWSW-UHFFFAOYSA-N 0.000 description 1
- LRBYNUPNHDOTJG-UHFFFAOYSA-N C(#N)C1(CC1)CNC=1C=C(C=2N(C1)N=CC2C#N)C=2C=NC(=CC2)N2CC1N(C(C2)C1)CC=1C=NC(=CC1)OC Chemical compound C(#N)C1(CC1)CNC=1C=C(C=2N(C1)N=CC2C#N)C=2C=NC(=CC2)N2CC1N(C(C2)C1)CC=1C=NC(=CC1)OC LRBYNUPNHDOTJG-UHFFFAOYSA-N 0.000 description 1
- VVKDUTSCBQIGLT-UHFFFAOYSA-N C(#N)C1(CC1)COC=1C=C(C=2N(C1)N=CC2C#N)C=2C=NC(=CC2)N2CC1N(C(C2)C1)CC=1C=NC(=C(C1)F)OC Chemical compound C(#N)C1(CC1)COC=1C=C(C=2N(C1)N=CC2C#N)C=2C=NC(=CC2)N2CC1N(C(C2)C1)CC=1C=NC(=C(C1)F)OC VVKDUTSCBQIGLT-UHFFFAOYSA-N 0.000 description 1
- RVDOXZQUZVOUNB-UHFFFAOYSA-N C(#N)C1(CC1)COC=1C=C(C=2N(C1)N=CC2C#N)C=2C=NC(=CC2)N2CC1N(C(C2)C1)CC=1C=NC(=CC1)OC Chemical compound C(#N)C1(CC1)COC=1C=C(C=2N(C1)N=CC2C#N)C=2C=NC(=CC2)N2CC1N(C(C2)C1)CC=1C=NC(=CC1)OC RVDOXZQUZVOUNB-UHFFFAOYSA-N 0.000 description 1
- RRHUZARQVSBUFO-UHFFFAOYSA-N C(#N)C1(CCC1)COC=1C=C(C=2N(C1)N=CC2C#N)C=2C=NC(=CC2)N2CC1N(C(C2)C1)CC=1C=NC(=CC1)OC Chemical compound C(#N)C1(CCC1)COC=1C=C(C=2N(C1)N=CC2C#N)C=2C=NC(=CC2)N2CC1N(C(C2)C1)CC=1C=NC(=CC1)OC RRHUZARQVSBUFO-UHFFFAOYSA-N 0.000 description 1
- WYQDPQSAFPSURY-UHFFFAOYSA-N C(#N)C1(CCCC1)COC=1C=C(C=2N(C1)N=CC2C#N)C=2C=NC(=CC2)N2CC1N(C(C2)C1)CC=1C=NC(=CC1)OC Chemical compound C(#N)C1(CCCC1)COC=1C=C(C=2N(C1)N=CC2C#N)C=2C=NC(=CC2)N2CC1N(C(C2)C1)CC=1C=NC(=CC1)OC WYQDPQSAFPSURY-UHFFFAOYSA-N 0.000 description 1
- VSMKIISRXWEWAC-UHFFFAOYSA-N C(#N)C1(CCOCC1)COC=1C=C(C=2N(C1)N=CC2C#N)C=2C=NC(=CC2)N2CC1N(C(C2)C1)CC=1C=NC(=CC1)OC Chemical compound C(#N)C1(CCOCC1)COC=1C=C(C=2N(C1)N=CC2C#N)C=2C=NC(=CC2)N2CC1N(C(C2)C1)CC=1C=NC(=CC1)OC VSMKIISRXWEWAC-UHFFFAOYSA-N 0.000 description 1
- GRFGLSAIOPSZNX-UHFFFAOYSA-N C(#N)C1(CN(C1)C=1C=C(C=2N(C1)N=CC2C#N)C=2C=NC(=CC2)N2CC1N(C(C2)C1)CC=1C=NC(=CC1)OC)C Chemical compound C(#N)C1(CN(C1)C=1C=C(C=2N(C1)N=CC2C#N)C=2C=NC(=CC2)N2CC1N(C(C2)C1)CC=1C=NC(=CC1)OC)C GRFGLSAIOPSZNX-UHFFFAOYSA-N 0.000 description 1
- RPMOVVBYQKVHPP-UHFFFAOYSA-N C(C)(C)C1=C(C(=CC(=C1)C(C)C)C(C)C)C1=CC=CC=C1.C(CCCCC)[P] Chemical group C(C)(C)C1=C(C(=CC(=C1)C(C)C)C(C)C)C1=CC=CC=C1.C(CCCCC)[P] RPMOVVBYQKVHPP-UHFFFAOYSA-N 0.000 description 1
- PJIVGSYBUDMNTO-UHFFFAOYSA-N C1(CC1)OC1=CC=C(C=N1)CN1C2CN(CC1C2)C2=CC=C(C=N2)C=2C=1N(C=C(C2)OCC(C)(C)O)N=CC1C#N Chemical compound C1(CC1)OC1=CC=C(C=N1)CN1C2CN(CC1C2)C2=CC=C(C=N2)C=2C=1N(C=C(C2)OCC(C)(C)O)N=CC1C#N PJIVGSYBUDMNTO-UHFFFAOYSA-N 0.000 description 1
- QMZOHIADFRPJBT-UHFFFAOYSA-N C=1C=C(N2C1C=CC=C2)C#N.CS(=O)(=O)CCC2=CC(=CC=N2)B2OC(C(O2)(C)C)(C)C Chemical compound C=1C=C(N2C1C=CC=C2)C#N.CS(=O)(=O)CCC2=CC(=CC=N2)B2OC(C(O2)(C)C)(C)C QMZOHIADFRPJBT-UHFFFAOYSA-N 0.000 description 1
- GSCLXORAYHLWKF-UHFFFAOYSA-N CC(C)(C#CC1=CN2C(=C(C=N2)C#N)C(=C1)C3=CN=C(C=C3)N4CC5CC(C4)N5CC6=CC(=C(N=C6)OC)F)N Chemical compound CC(C)(C#CC1=CN2C(=C(C=N2)C#N)C(=C1)C3=CN=C(C=C3)N4CC5CC(C4)N5CC6=CC(=C(N=C6)OC)F)N GSCLXORAYHLWKF-UHFFFAOYSA-N 0.000 description 1
- LXORLXOIENNNML-UHFFFAOYSA-N CC(C)(C1CN(C1)C2=CN3C(=C(C=N3)C#N)C(=C2)C4=CN=C(C=C4)N5CC6CC(C5)N6CC7=CN=C(C=C7)OC8CC8)O Chemical compound CC(C)(C1CN(C1)C2=CN3C(=C(C=N3)C#N)C(=C2)C4=CN=C(C=C4)N5CC6CC(C5)N6CC7=CN=C(C=C7)OC8CC8)O LXORLXOIENNNML-UHFFFAOYSA-N 0.000 description 1
- BBYADOHTQAPMMX-UHFFFAOYSA-N CC1(CCN(CC1)C2=NC=C(C=C2)C3=CC(=CN4C3=C(C=N4)C#N)Br)NC(=O)OC(C)(C)C Chemical compound CC1(CCN(CC1)C2=NC=C(C=C2)C3=CC(=CN4C3=C(C=N4)C#N)Br)NC(=O)OC(C)(C)C BBYADOHTQAPMMX-UHFFFAOYSA-N 0.000 description 1
- SZIQDPFGJIRONI-UHFFFAOYSA-N CC1(CCN(CC1)C2=NC=C(C=C2)C3=CC(=CN4C3=C(C=N4)C#N)N5CC6(C5)CC(C6)(C)O)NC(=O)C7=C(C=CC=N7)Cl Chemical compound CC1(CCN(CC1)C2=NC=C(C=C2)C3=CC(=CN4C3=C(C=N4)C#N)N5CC6(C5)CC(C6)(C)O)NC(=O)C7=C(C=CC=N7)Cl SZIQDPFGJIRONI-UHFFFAOYSA-N 0.000 description 1
- VTGGVURLELNFMW-UHFFFAOYSA-N CC1(CCN(CC1)C2=NC=C(C=C2)C3=CC(=CN4C3=C(C=N4)C#N)O)NC(=O)C5=C(C=CC=N5)F Chemical compound CC1(CCN(CC1)C2=NC=C(C=C2)C3=CC(=CN4C3=C(C=N4)C#N)O)NC(=O)C5=C(C=CC=N5)F VTGGVURLELNFMW-UHFFFAOYSA-N 0.000 description 1
- YCSGHNDBIDQELT-UHFFFAOYSA-N CC1(CCN(CC1)C2=NC=C(C=C2)C3=CC(=CN4C3=C(C=N4)C#N)OCC5(COC5)C#N)NC(=O)C6=C(C=CC=N6)Cl Chemical compound CC1(CCN(CC1)C2=NC=C(C=C2)C3=CC(=CN4C3=C(C=N4)C#N)OCC5(COC5)C#N)NC(=O)C6=C(C=CC=N6)Cl YCSGHNDBIDQELT-UHFFFAOYSA-N 0.000 description 1
- YUAXQCQRGOZBQM-UHFFFAOYSA-N CC1=CC=C(C=C1)S(=O)(=O)OCC12CC(C1)(C2)C(N)=O Chemical compound CC1=CC=C(C=C1)S(=O)(=O)OCC12CC(C1)(C2)C(N)=O YUAXQCQRGOZBQM-UHFFFAOYSA-N 0.000 description 1
- CQSSWJBZRXTWPQ-UHFFFAOYSA-N CC1=CC=C(C=C1)S(=O)(=O)OCC12CC(C1)(C2)C(NC)=O Chemical compound CC1=CC=C(C=C1)S(=O)(=O)OCC12CC(C1)(C2)C(NC)=O CQSSWJBZRXTWPQ-UHFFFAOYSA-N 0.000 description 1
- XYGKGASSKJWLTN-UHFFFAOYSA-N CCCCCCC.CCCCCCC Chemical compound CCCCCCC.CCCCCCC XYGKGASSKJWLTN-UHFFFAOYSA-N 0.000 description 1
- UXEMCDFWPAWWDD-UHFFFAOYSA-N COC1=CC=C(C=N1)CN1C2CN(CC1C2)C1=NC=C(C=C1)B1OC(C(O1)(C)C)(C)C Chemical compound COC1=CC=C(C=N1)CN1C2CN(CC1C2)C1=NC=C(C=C1)B1OC(C(O1)(C)C)(C)C UXEMCDFWPAWWDD-UHFFFAOYSA-N 0.000 description 1
- XJMKISPBQCFNQB-UHFFFAOYSA-N COC1=CC=C(C=N1)CN1C2CN(CC1C2)C2=CC=C(C=N2)OB(O)O Chemical compound COC1=CC=C(C=N1)CN1C2CN(CC1C2)C2=CC=C(C=N2)OB(O)O XJMKISPBQCFNQB-UHFFFAOYSA-N 0.000 description 1
- FBKZPTZBNOZFCN-UHFFFAOYSA-N COC1=NC=C(C=C1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)C#CC(CF)(CF)O Chemical compound COC1=NC=C(C=C1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)C#CC(CF)(CF)O FBKZPTZBNOZFCN-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- WNWCHQMTCOQLPO-UHFFFAOYSA-N Cc1ccc(cc1)S(=O)(=O)OCC1(CCOCC1)C#N Chemical compound Cc1ccc(cc1)S(=O)(=O)OCC1(CCOCC1)C#N WNWCHQMTCOQLPO-UHFFFAOYSA-N 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical group ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 1
- APGXLDRXEJSLLG-UHFFFAOYSA-N ClC=1C(=NC=CC1)C(=O)NC1(CCN(CC1)C1=NC=C(C=C1)C=1C=2N(C=C(C1)C#CC(C)(C)O)N=CC2C#N)C Chemical compound ClC=1C(=NC=CC1)C(=O)NC1(CCN(CC1)C1=NC=C(C=C1)C=1C=2N(C=C(C1)C#CC(C)(C)O)N=CC2C#N)C APGXLDRXEJSLLG-UHFFFAOYSA-N 0.000 description 1
- KVUZXCIWKGEHAZ-UHFFFAOYSA-N ClC=1C(=NC=CC1)C(=O)NC1(CCN(CC1)C1=NC=C(C=C1)C=1C=2N(C=C(C1)N1CC(C1)(C)O)N=CC2C#N)C Chemical compound ClC=1C(=NC=CC1)C(=O)NC1(CCN(CC1)C1=NC=C(C=C1)C=1C=2N(C=C(C1)N1CC(C1)(C)O)N=CC2C#N)C KVUZXCIWKGEHAZ-UHFFFAOYSA-N 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000027205 Congenital disease Diseases 0.000 description 1
- 101150086096 Eif2ak3 gene Proteins 0.000 description 1
- MDIAKIHKBBNYHF-UHFFFAOYSA-N Ethyl 2-(methylthio)acetate Chemical compound CCOC(=O)CSC MDIAKIHKBBNYHF-UHFFFAOYSA-N 0.000 description 1
- XJJXGQCCZBMQST-UHFFFAOYSA-N FC=1C=C(C=NC1OC)CN1C2CN(CC1C2)C2=CC=C(C=N2)C=2C=1N(C=C(C2)OCC23CC(C2)(C3)O)N=CC1C#N Chemical compound FC=1C=C(C=NC1OC)CN1C2CN(CC1C2)C2=CC=C(C=N2)C=2C=1N(C=C(C2)OCC23CC(C2)(C3)O)N=CC1C#N XJJXGQCCZBMQST-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 101001050559 Homo sapiens Kinesin-1 heavy chain Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 102100023422 Kinesin-1 heavy chain Human genes 0.000 description 1
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 description 1
- ZOKGHGHZBSCLQY-UHFFFAOYSA-N N-[1-[5-(3-cyano-6-hydroxypyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl]-4-methylpiperidin-4-yl]-3-(fluoromethyl)pyridine-2-carboxamide Chemical compound CC1(CCN(CC1)C2=NC=C(C=C2)C3=CC(=CN4C3=C(C=N4)C#N)O)NC(=O)C5=C(C=CC=N5)CF ZOKGHGHZBSCLQY-UHFFFAOYSA-N 0.000 description 1
- UEJJDKVABAFTOO-UHFFFAOYSA-N N-[1-[5-[6-[2-(1-aminocyclopropyl)ethynyl]-3-cyanopyrazolo[1,5-a]pyridin-4-yl]pyridin-2-yl]-4-methylpiperidin-4-yl]-3-(chloromethyl)pyridine-2-carboxamide Chemical compound CC1(CCN(CC1)C2=NC=C(C=C2)C3=CC(=CN4C3=C(C=N4)C#N)C#CC5(CC5)N)NC(=O)C6=C(C=CC=N6)CCl UEJJDKVABAFTOO-UHFFFAOYSA-N 0.000 description 1
- WIEBANYTCXIUBE-UHFFFAOYSA-N NC1(CC1)C#CC=1C=C(C=2N(C1)N=CC2C#N)C=2C=NC(=CC2)N2CC1N(C(C2)C1)CC=1C=NC(=CC1)OC Chemical compound NC1(CC1)C#CC=1C=C(C=2N(C1)N=CC2C#N)C=2C=NC(=CC2)N2CC1N(C(C2)C1)CC=1C=NC(=CC1)OC WIEBANYTCXIUBE-UHFFFAOYSA-N 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- KUKVAEGBHLWUFR-HPRDVNIFSA-N OC(C#CC=1C=C(C=2N(C1)N=CC2C#N)C=2C=NC(=CC2)N2CC1N(C(C2)C1)CC=1C=NC(=CC1)OC([2H])([2H])[2H])(C)C Chemical compound OC(C#CC=1C=C(C=2N(C1)N=CC2C#N)C=2C=NC(=CC2)N2CC1N(C(C2)C1)CC=1C=NC(=CC1)OC([2H])([2H])[2H])(C)C KUKVAEGBHLWUFR-HPRDVNIFSA-N 0.000 description 1
- AZUSYDLSCBTUDK-UHFFFAOYSA-N OC(C#CC=1C=C(C=2N(C1)N=CC2C#N)C=2C=NC(=CC2)N2CC1N(C(C2)C1)CC=1C=NC(=CC1)OC)(COC)C Chemical compound OC(C#CC=1C=C(C=2N(C1)N=CC2C#N)C=2C=NC(=CC2)N2CC1N(C(C2)C1)CC=1C=NC(=CC1)OC)(COC)C AZUSYDLSCBTUDK-UHFFFAOYSA-N 0.000 description 1
- KEVNRIVERUXMNF-UHFFFAOYSA-N OC1(CC2(CN(C2)C=2C=C(C=3N(C2)N=CC3C#N)C=3C=NC(=CC3)N3CC2N(C(C3)C2)CC=2C=NC(=CC2)OC)C1)C Chemical compound OC1(CC2(CN(C2)C=2C=C(C=3N(C2)N=CC3C#N)C=3C=NC(=CC3)N3CC2N(C(C3)C2)CC=2C=NC(=CC2)OC)C1)C KEVNRIVERUXMNF-UHFFFAOYSA-N 0.000 description 1
- QNNXTJONGGFBKC-UHFFFAOYSA-N OC1(CCC1)C#CC=1C=C(C=2N(C1)N=CC2C#N)C=2C=NC(=CC2)N2CC1N(C(C2)C1)CC=1C=NC(=CC1)OC Chemical compound OC1(CCC1)C#CC=1C=C(C=2N(C1)N=CC2C#N)C=2C=NC(=CC2)N2CC1N(C(C2)C1)CC=1C=NC(=CC1)OC QNNXTJONGGFBKC-UHFFFAOYSA-N 0.000 description 1
- FDEIQXJCICFKNA-UHFFFAOYSA-N OC1(CCN(CC1)C=1C=C(C=2N(C1)N=CC2C#N)C=2C=NC(=CC2)N2CC1N(C(C2)C1)CC=1C=NC(=CC1)OC)C Chemical compound OC1(CCN(CC1)C=1C=C(C=2N(C1)N=CC2C#N)C=2C=NC(=CC2)N2CC1N(C(C2)C1)CC=1C=NC(=CC1)OC)C FDEIQXJCICFKNA-UHFFFAOYSA-N 0.000 description 1
- WATVGYIHNUZPBE-UHFFFAOYSA-N OC1(CN(CC1)C=1C=C(C=2N(C1)N=CC2C#N)C=2C=NC(=CC2)N2CC1N(C(C2)C1)CC=1C=NC(=CC1)OC)C Chemical compound OC1(CN(CC1)C=1C=C(C=2N(C1)N=CC2C#N)C=2C=NC(=CC2)N2CC1N(C(C2)C1)CC=1C=NC(=CC1)OC)C WATVGYIHNUZPBE-UHFFFAOYSA-N 0.000 description 1
- LBNZZEGJSKBAFG-PNEAOOGRSA-N O[C@@H](C#CC=1C=C(C=2N(C1)N=CC2C#N)C=2C=NC(=CC2)N2CC1N(C(C2)C1)CC=1C=NC(=CC1)OC)C Chemical compound O[C@@H](C#CC=1C=C(C=2N(C1)N=CC2C#N)C=2C=NC(=CC2)N2CC1N(C(C2)C1)CC=1C=NC(=CC1)OC)C LBNZZEGJSKBAFG-PNEAOOGRSA-N 0.000 description 1
- LBNZZEGJSKBAFG-CCYWVKEMSA-N O[C@H](C#CC=1C=C(C=2N(C1)N=CC2C#N)C=2C=NC(=CC2)N2CC1N(C(C2)C1)CC=1C=NC(=CC1)OC)C Chemical compound O[C@H](C#CC=1C=C(C=2N(C1)N=CC2C#N)C=2C=NC(=CC2)N2CC1N(C(C2)C1)CC=1C=NC(=CC1)OC)C LBNZZEGJSKBAFG-CCYWVKEMSA-N 0.000 description 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 1
- JDDHUROHDHPVIO-UHFFFAOYSA-N Piperazine citrate Chemical compound C1CNCCN1.C1CNCCN1.C1CNCCN1.OC(=O)CC(O)(C(O)=O)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O JDDHUROHDHPVIO-UHFFFAOYSA-N 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000534944 Thia Species 0.000 description 1
- 229910004338 Ti-S Inorganic materials 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- HLYMGXKSPKAKNF-UHFFFAOYSA-N [1-(bromomethyl)cyclopropyl]carbamic acid Chemical compound OC(=O)NC1(CBr)CC1 HLYMGXKSPKAKNF-UHFFFAOYSA-N 0.000 description 1
- MVIJROZDUFZNBY-HPRDVNIFSA-N [2H]C([2H])([2H])OC1=NC=C(C=C1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)C#CC(C)(C)N Chemical compound [2H]C([2H])([2H])OC1=NC=C(C=C1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)C#CC(C)(C)N MVIJROZDUFZNBY-HPRDVNIFSA-N 0.000 description 1
- KLIQFXGEHXWEHO-FIBGUPNXSA-N [2H]C([2H])([2H])OC1=NC=C(C=C1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)OCC78CC(C7)(C8)O Chemical compound [2H]C([2H])([2H])OC1=NC=C(C=C1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)OCC78CC(C7)(C8)O KLIQFXGEHXWEHO-FIBGUPNXSA-N 0.000 description 1
- ZBIKORITPGTTGI-UHFFFAOYSA-N [acetyloxy(phenyl)-$l^{3}-iodanyl] acetate Chemical compound CC(=O)OI(OC(C)=O)C1=CC=CC=C1 ZBIKORITPGTTGI-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- BVCZEBOGSOYJJT-UHFFFAOYSA-N ammonium carbamate Chemical compound [NH4+].NC([O-])=O BVCZEBOGSOYJJT-UHFFFAOYSA-N 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- ORCXPYPDHLVQFP-UHFFFAOYSA-N bicyclo[1.1.1]pentane-3-carboxylic acid Chemical compound C1C2CC1(C(=O)O)C2 ORCXPYPDHLVQFP-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 description 1
- 229960001292 cabozantinib Drugs 0.000 description 1
- FGNLEIGUMSBZQP-UHFFFAOYSA-N cadaverine dihydrochloride Chemical compound Cl.Cl.NCCCCCN FGNLEIGUMSBZQP-UHFFFAOYSA-N 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000013098 chemical test method Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000008711 chromosomal rearrangement Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- GFBLFDSCAKHHGX-UHFFFAOYSA-N cyclobutanecarbonitrile Chemical compound N#CC1CCC1 GFBLFDSCAKHHGX-UHFFFAOYSA-N 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- YOXHCYXIAVIFCZ-UHFFFAOYSA-N cyclopropanol Chemical compound OC1CC1 YOXHCYXIAVIFCZ-UHFFFAOYSA-N 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 150000001975 deuterium Chemical group 0.000 description 1
- BSHICDXRSZQYBP-UHFFFAOYSA-N dichloromethane;palladium(2+) Chemical compound [Pd+2].ClCCl BSHICDXRSZQYBP-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 125000005052 dihydropyrazolyl group Chemical group N1(NCC=C1)* 0.000 description 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000000105 enteric nervous system Anatomy 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- YSNWHRKJEKWJNY-UHFFFAOYSA-N ethyl 3-(methylthio)propionate Chemical compound CCOC(=O)CCSC YSNWHRKJEKWJNY-UHFFFAOYSA-N 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Substances NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000009916 joint effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- IHLVCKWPAMTVTG-UHFFFAOYSA-N lithium;carbanide Chemical compound [Li+].[CH3-] IHLVCKWPAMTVTG-UHFFFAOYSA-N 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 210000003794 male germ cell Anatomy 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Substances CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 1
- UIUXUFNYAYAMOE-UHFFFAOYSA-N methylsilane Chemical compound [SiH3]C UIUXUFNYAYAMOE-UHFFFAOYSA-N 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 210000004412 neuroendocrine cell Anatomy 0.000 description 1
- HKKDKUMUWRTAIA-UHFFFAOYSA-N nitridooxidocarbon(.) Chemical compound [O]C#N HKKDKUMUWRTAIA-UHFFFAOYSA-N 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 235000020925 non fasting Nutrition 0.000 description 1
- WSGCRAOTEDLMFQ-UHFFFAOYSA-N nonan-5-one Chemical compound CCCCC(=O)CCCC WSGCRAOTEDLMFQ-UHFFFAOYSA-N 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- XCRBXWCUXJNEFX-UHFFFAOYSA-N peroxybenzoic acid Chemical compound OOC(=O)C1=CC=CC=C1 XCRBXWCUXJNEFX-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 238000013031 physical testing Methods 0.000 description 1
- 229960005141 piperazine Drugs 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000011112 process operation Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- TVDSBUOJIPERQY-UHFFFAOYSA-N prop-2-yn-1-ol Chemical compound OCC#C TVDSBUOJIPERQY-UHFFFAOYSA-N 0.000 description 1
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 1
- 229940121610 selpercatinib Drugs 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- RSIJVJUOQBWMIM-UHFFFAOYSA-L sodium sulfate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O RSIJVJUOQBWMIM-UHFFFAOYSA-L 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- OUFBVDKNEWUFHP-UHFFFAOYSA-N tert-butyl 3,6-diazabicyclo[3.1.1]heptane-6-carboxylate Chemical compound C1C2N(C(=O)OC(C)(C)C)C1CNC2 OUFBVDKNEWUFHP-UHFFFAOYSA-N 0.000 description 1
- LJHNBDANXGYHLH-UHFFFAOYSA-N tert-butyl 3-[5-(6-bromo-3-cyanopyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl]-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate Chemical compound BrC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=CC(=NC=1)N1CC2N(C(C1)C2)C(=O)OC(C)(C)C LJHNBDANXGYHLH-UHFFFAOYSA-N 0.000 description 1
- JKOYVQLNDHSKID-UHFFFAOYSA-N tert-butyl N-(1-hydroxycyclopropyl)carbamate Chemical compound CC(C)(C)OC(=O)NC1(CC1)O JKOYVQLNDHSKID-UHFFFAOYSA-N 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- YODQQARABJQLIP-UHFFFAOYSA-N thian-4-ol Chemical compound OC1CCSCC1 YODQQARABJQLIP-UHFFFAOYSA-N 0.000 description 1
- LMVCLDAMMNHILO-UHFFFAOYSA-N thian-4-ylmethanol Chemical compound OCC1CCSCC1 LMVCLDAMMNHILO-UHFFFAOYSA-N 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 230000002100 tumorsuppressive effect Effects 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- JABYJIQOLGWMQW-UHFFFAOYSA-N undec-4-ene Chemical compound CCCCCCC=CCCC JABYJIQOLGWMQW-UHFFFAOYSA-N 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Definitions
- the invention belongs to the field of medicine and biology, and in particular relates to a crystal form containing a free base of a bi-cyclic derivative inhibitor and a preparation method and application thereof.
- RET rearranged during transfection protein
- RET located on chromosome 10. It is a receptor tyrosine kinase consisting of an extracellular domain, a transmembrane domain and an intracellular kinase domain.
- RET ligands are glial cell-derived neurotrophic factor (GDNF) family ligands (GFLs) such as GDNF, neurturin (NRTN), artemin (ARTN), persephin (PSPN), and activation of the receptor also requires the co-receptor GFR ⁇
- GFLs and GFR ⁇ form a dimer, bind RET and recruit it to the cholesterol-rich membrane region, the RET protein dimerizes and autophosphorylates, thereby activating the downstream RAS-MAPK, PI3K-AKT , PKC and other signaling pathways.
- RET plays an important role in the development of the kidney and enteric nervous system during embryonic development; it is also important for the homeostasis of tissues such as neuroendocrine, hematopoietic and male germ cells.
- RET protein function leads to the occurrence of various diseases. Loss of RET protein function during development can lead to a series of congenital diseases such as Hirschsprung disease (HSCR) and congenital malformations of the kidney and urinary tract (CAKUT).
- HSCR Hirschsprung disease
- CAKUT congenital malformations of the kidney and urinary tract
- RET fusions mainly occur in 1-2% of non-small cell lung cancer (NSCLC) patients and 5-10% of papillary thyroid carcinomas, while RET mutations mainly occur in 60% of medullary thyroid carcinomas.
- NSCLC non-small cell lung cancer
- RET mutations mainly occur in 60% of medullary thyroid carcinomas.
- Activating mutations are found in many other tumors such as breast cancer, gastric cancer, intestinal cancer, chronic myelomonocytic leukemia, etc.
- MKI multi-kinase inhibitors
- vandetinib and cabozantinib are mostly used in clinical medicine. Due to their poor selectivity, these multi-kinase inhibitors have the disadvantages of high side effects and poor efficacy, and they cannot overcome the treatment process. drug resistance problems.
- RET-targeted drugs have attracted a large number of domestic and foreign pharmaceutical companies to develop RET-specific targeted drugs.
- LOXO-292 of Loxo Oncology which has entered clinical phase I/II, and BLU of Blueprint, are more prominent.
- -667 has also entered clinical phase I.
- Both of these two targeted drugs have shown very good efficacy and good safety in patients with RET activating mutations in preclinical trials, and at the same time, they have also overcome possible drug resistance mutations in preclinical activity screening. , which is expected to bring more treatment options for cancers with RET-activating mutations in the future.
- RET inhibitors with higher selectivity, better activity, better safety, and can overcome drug resistance mutations have the potential to treat a variety of cancers and have broad market prospects.
- the PCT patent (application number: PCT/CN2020/090142) of Jiangsu Hansoh Pharmaceutical Group Co., Ltd. discloses a series of structures containing bicyclic derivative inhibitors.
- the present invention has conducted comprehensive research on the free bases of the above substances, and is committed to obtaining a stable crystal form suitable for later drug development with simple process operation, easy storage and high bioavailability.
- the object of the present invention is to provide a crystal form of the compound represented by the general formula (I),
- L is selected from -CH2- or -NHC(O)-;
- M is selected from CR or N;
- R is selected from hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-8 cycloalkyl, 3- 8-membered heterocyclyl, C 6-10 -membered aryl or 5-12-membered heteroaryl;
- X 1 is selected from CR a or N;
- X 2 is selected from CR b or N;
- R a and R b are each independently selected from hydrogen, deuterium, halogen, amino, nitro, hydroxy, cyano, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl, C 2-6 alkenyl, C 2-6 alkynyl , C 3- 8 -cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl or 5-12 membered heteroaryl;
- R 1 , R 2 and R 3 are each independently selected from hydrogen, deuterium, halogen, amino, nitro, hydroxy, cyano, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkane base, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-8 cycloalkyl, 3-8 membered heterocyclyl, C 6-10 aryl or 5-12 membered heteroaryl;
- R 5 and R 6 are each independently selected from hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl, C 2-6 alkenyl, C 2-6 alkynyl , C 3- 8 -cycloalkyl, 3-8-membered heterocyclyl, C 6-10 -membered aryl or 5-12-membered heteroaryl, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl , C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-8 cycloalkyl, 3-8 membered
- R 7 and R 8 are each independently selected from hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl, C 2-6 alkenyl, C 2-6 alkynyl , C 3- 8 -cycloalkyl, 3-8-membered heterocyclyl, C 6-10 -membered aryl or 5-12-membered heteroaryl, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl , C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-8 cycloalkyl, 3-8 membered
- n 0, 1, 2 or 3;
- n 0, 1, 2, or 3;
- t 0, 1, 2 or 3.
- M is selected from CR or N;
- R is selected from hydrogen, amino or C 1-3 alkyl
- X 1 is selected from CR a or N;
- X 2 is selected from CR b or N;
- R a and R b are selected from each independently hydrogen, deuterium, halogen, C 1-3 alkyl or C 1-3 alkoxy;
- R 1 , R 2 and R 3 are each independently selected from hydrogen, deuterium, halogen, C 1-3 alkyl or C 1-3 alkoxy;
- Hydrogen, fluorine, chlorine, methyl or methoxy are preferred.
- R 5 is selected from hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, C 1-3 alkyl, C 1-3 deuterated alkyl, C 1-3 haloalkyl, C 1-3 alkoxy , C 1-3 deuterated alkoxy, C 1-3 haloalkoxy, C 1-3 hydroxyalkyl, C 2-3 alkenyl, C 2-3 alkynyl, C 3-6 cycloalkyl or 3 -8-membered heterocyclyl, C 1-3 alkyl, C 1-3 deuterated alkyl, C 1-3 haloalkyl, C 1-3 alkoxy, C 1-3 deuterated alkoxy, C 1 -3 haloalkoxy, C 1-3 hydroxyalkyl, C 2-3 alkenyl, C 2-3 alkynyl, C 3-3 cycloalkyl and 3-8 membered heterocyclyl, optionally further deuterium , halogen, amino, nitro, hydroxyl, cyano, C
- R 6 is selected from hydrogen, deuterium, halogen, amino, hydroxyl or C 1-3 alkyl
- R 7 and R 8 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxy or C 1-3 alkyl;
- n 0, 1, 2, or 3;
- n 0, 1, 2 or 3.
- the compound is further represented by the general formula (II):
- R 2 is selected from hydrogen, fluorine or chlorine
- R 4 is selected from -O(CH 2 ) m R 5 , -(CH 2 ) m R 5 or -NR 6 (CH 2 ) m R 5 ,
- R 5 is selected from C 2-3 alkynyl, optionally further by deuterium, halogen, amino, nitro, hydroxyl, cyano, C 1-3 alkyl, C 1-3 deuterated alkyl, C 1-3 One or more of haloalkyl, C 1-3 alkoxy, C 1-3 deuterated alkoxy, C 1-3 haloalkoxy, C 1-3 hydroxyalkyl or C 3-6 cycloalkyl Substituents are substituted.
- the compound is 6-(((R)-2-hydroxy-2-methylbut-3-yn-1-yl)oxy)-4-(6-(6- ((6-Methoxypyridin-3-yl)methyl)-3,6diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5- a] Pyridine-3-carbonitrile, characterized in that the crystal form is crystal form I, crystal form II, crystal form III, crystal form IV or crystal form V.
- the X-ray powder diffraction pattern of Form I has a diffraction peak at 2 ⁇ of 5.0 ⁇ 0.2°; or a diffraction peak at 9.6 ⁇ 0.2°; or a diffraction peak at 15.0 ⁇ 0.2°; or a diffraction peak at 17.2 ⁇ 0.2° or a diffraction peak at 22.2 ⁇ 0.2°; or a diffraction peak at 19.4 ⁇ 0.2°; or a diffraction peak at 30.2 ⁇ 0.2°; or a diffraction peak at 8.2 ⁇ 0.2°; or Has a diffraction peak at 25.1 ⁇ 0.2°; or has a diffraction peak at 26.9 ⁇ 0.2°; preferably includes any 2-5, or 3-5, or 3-6, or 3- 8 places, or 5-8 places, or 6-8 places; more preferably including any 6 places, 7 places or 8 places,
- the X-ray powder diffraction pattern of Form I has a diffraction peak at 2 ⁇ of 5.0 ⁇ 0.2°; or has a diffraction peak at 8.2 ⁇ 0.2°; or has a diffraction peak at 9.6 ⁇ 0.2°; or has a diffraction peak at 12.9 ⁇ 0.2° or a diffraction peak at 15.0 ⁇ 0.2°; or a diffraction peak at 17.2 ⁇ 0.2°; or a diffraction peak at 15.4 ⁇ 0.2°; or a diffraction peak at 16.6 ⁇ 0.2°; or Has a diffraction peak at 17.7 ⁇ 0.2°; or has a diffraction peak at 18.5 ⁇ 0.2°; preferably includes any 2-5, or 3-5, or 3-6, or 3- 8 places, or 5-8 places, or 6-8 places; more preferably including any 6 places, 7 places or 8 places;
- the X-ray powder diffraction pattern of crystal form I at least contains one or more diffraction peaks located at 2 ⁇ of 5.0 ⁇ 0.2°, 9.6 ⁇ 0.2°, 15.0 ⁇ 0.2°, and preferably contains two of them , more preferably contains 3 places; optionally, it can further contain at least one of 2 ⁇ of 17.2 ⁇ 0.2°, 22.2 ⁇ 0.2°, 19.4 ⁇ 0.2°, 30.2 ⁇ 0.2° or 8.2 ⁇ 0.2°, preferably including wherein 2, 3, 4 or 5;
- diffraction peaks located at 2 ⁇ of 5.0 ⁇ 0.2°, 9.6 ⁇ 0.2°, 15.0 ⁇ 0.2°, 17.2 ⁇ 0.2°, 22.2 ⁇ 0.2° and 8.2 ⁇ 0.2°;
- the X-ray powder diffraction pattern of crystal form I at least contains one or more diffraction peaks located at 2 ⁇ of 5.0 ⁇ 0.2°, 8.2 ⁇ 0.2°, 9.6 ⁇ 0.2°, preferably 2 of them, more preferably 3 of them
- it may further comprise at least one of 2 ⁇ being 12.9 ⁇ 0.2°, 15.0 ⁇ 0.2°, 17.2 ⁇ 0.2°, 15.4 ⁇ 0.2° or 16.6 ⁇ 0.2°, preferably including 2, 3, 4 or 5;
- diffraction peaks located at 2 ⁇ of 8.2 ⁇ 0.2°, 9.6 ⁇ 0.2°, 12.9 ⁇ 0.2°, 15.0 ⁇ 0.2°, 17.2 ⁇ 0.2° and 15.4 ⁇ 0.2°;
- diffraction peaks located at 2 ⁇ of 9.6 ⁇ 0.2°, 12.9 ⁇ 0.2°, 15.0 ⁇ 0.2°, 17.2 ⁇ 0.2°, 15.4 ⁇ 0.2° and 16.6 ⁇ 0.2°;
- diffraction peaks located at 2 ⁇ of 5.0 ⁇ 0.2°, 9.6 ⁇ 0.2°, 12.9 ⁇ 0.2°, 15.0 ⁇ 0.2°, 17.2 ⁇ 0.2° and 15.4 ⁇ 0.2°;
- diffraction peaks located at 2 ⁇ of 8.2 ⁇ 0.2°, 12.9 ⁇ 0.2°, 15.0 ⁇ 0.2°, 17.2 ⁇ 0.2°, 15.4 ⁇ 0.2° and 16.6 ⁇ 0.2°;
- the X-ray powder diffraction pattern of Form I optionally further comprises a 2 ⁇ of 10.0 ⁇ 0.2°, 25.4 ⁇ 0.2°, 26.9 ⁇ 0.2°, 13.0 ⁇ 0.2°, 12.9 ⁇ 0.2° or 20.0 ⁇ 0.2
- One or more diffraction peaks preferably at least any 2-3, or 4-5, or 6-7 of them; more preferably, any 2, 3, 4, 5, or 6 of them , 7;
- the preferred X-ray powder diffraction pattern of Form I optionally further comprises a 2 ⁇ of 15.4 ⁇ 0.2°, 16.6 ⁇ 0.2°, 17.7 ⁇ 0.2°, 18.5 ⁇ 0.2°, 19.3 ⁇ 0.2° or 24.0 ⁇ 0.2
- the X-ray powder diffraction pattern of Form I comprises 2 ⁇ at 5.0 ⁇ 0.2°, 9.6 ⁇ 0.2°, 15.0 ⁇ 0.2°, 17.2 ⁇ 0.2°, 22.2 ⁇ 0.2°, 19.4 ⁇ 0.2°, 30.2 ⁇
- the X-ray powder diffraction pattern of Form I has diffraction peaks at the following positions at 2 ⁇ :
- the X-ray powder diffraction pattern of Form I comprises 2 ⁇ at 5.0 ⁇ 0.2°, 8.2 ⁇ 0.2°, 9.6 ⁇ 0.2°, 12.9 ⁇ 0.2°, 15.0 ⁇ 0.2°, 17.2 ⁇ 0.2°, 15.4 ⁇
- the X-ray powder diffraction pattern of Form I has diffraction peaks at the following positions at 2 ⁇ :
- Example 63 of the present invention 6-(((R)-2-hydroxy-2-methylbut-3-yn-1-yl)oxy)-4-(6-(6-((6- Methoxypyridin-3-yl)methyl)-3,6diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine- 3-carbonitrile crystal form I, its X-ray powder diffraction pattern is basically shown in Figure 1; its DSC pattern is basically shown in Figure 2, the melting point of crystal form I is 216.8 ⁇ 218.4 ° C; its TGA pattern is basically shown in Figure 3 shown.
- the compound shown in Example 63 is 6-((((R)-2-hydroxy-2-methylbut-3-yn-1-yl)oxy)-4-(6 -(6-((6-Methoxypyridin-3-yl)methyl)-3,6diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[ 1,5-a]pyridine-3-carbonitrile crystal form II.
- the X-ray powder diffraction pattern of Form II contains at least one or more diffraction peaks located at 2 ⁇ of 4.8 ⁇ 0.2°, 17.7 ⁇ 0.2°, 16.6 ⁇ 0.2°, preferably 2 of them, more preferably 3 of them Optionally, it may further comprise at least one of 2 ⁇ being 9.4 ⁇ 0.2°, 18.4 ⁇ 0.2°, 19.1 ⁇ 0.2°, 17.0 ⁇ 0.2° or 18.6 ⁇ 0.2°, preferably including 2, 3, 4 or 5;
- diffraction peaks located at 2 ⁇ of 4.8 ⁇ 0.2°, 17.7 ⁇ 0.2°, 16.6 ⁇ 0.2°, 9.4 ⁇ 0.2°, 18.4 ⁇ 0.2° and 19.1 ⁇ 0.2°;
- diffraction peaks located at 2 ⁇ of 4.8 ⁇ 0.2°, 17.7 ⁇ 0.2°, 9.4 ⁇ 0.2°, 18.4 ⁇ 0.2°, 19.1 ⁇ 0.2° and 17.0 ⁇ 0.2°;
- the X-ray powder diffraction pattern of Form II optionally further comprises positions at 2 ⁇ of 4.5 ⁇ 0.2°, 15.4 ⁇ 0.2°, 14.6 ⁇ 0.2°, 24.0 ⁇ 0.2°, 21.5 ⁇ 0.2°, 20.5 ⁇ 0.2° or One or more diffraction peaks in 18.0 ⁇ 0.2; preferably at least any 2-3, or 4-5, or 6-7 of them; more preferably, any 2, 3, 4, 5, 6, 7;
- the X-ray powder diffraction pattern of the crystal form II comprises 2 ⁇ at 4.8 ⁇ 0.2°, 17.7 ⁇ 0.2°, 16.6 ⁇ 0.2°, 9.4 ⁇ 0.2°, 18.4 ⁇ 0.2°, 19.1 ⁇ 0.2°, 17.0 ⁇
- the X-ray powder diffraction pattern of Form II has diffraction peaks at the following positions at 2 ⁇ :
- the X-ray powder diffraction pattern of the crystal form II comprises 2 ⁇ at 4.8 ⁇ 0.2°, 17.7 ⁇ 0.2°, 16.6 ⁇ 0.2°, 9.4 ⁇ 0.2°, 18.4 ⁇ 0.2°, 19.1 ⁇ 0.2°, 17.0 ⁇ 0.2°, 18.6 ⁇ 0.2°, 4.5 ⁇ 0.2°, 15.4 ⁇ 0.2°, 14.6 ⁇ 0.2°, 24.0 ⁇ 0.2°, 21.5 ⁇ 0.2°, 20.5 ⁇ 0.2°, 18.0 ⁇ 0.2, 26.0 ⁇ 0.2°, 22.0 ⁇ 0.2
- Example 63 of the present invention 6-(((R)-2-hydroxy-2-methylbut-3-yn-1-yl)oxy)-4-(6-(6-((6 -Methoxypyridin-3-yl)methyl)-3,6diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine -3-carbonitrile crystal form II, its X-ray powder diffraction pattern is basically shown in Figure 4; its DSC pattern is basically shown in Figure 5; its TGA pattern is basically shown in Figure 6.
- the compound shown in Example 63 is 6-((((R)-2-hydroxy-2-methylbut-3-yn-1-yl)oxy)-4-(6 -(6-((6-Methoxypyridin-3-yl)methyl)-3,6diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[ 1,5-a]pyridine-3-carbonitrile crystal form III.
- the X-ray powder diffraction pattern of Form III has a diffraction peak at 2 ⁇ of 4.6 ⁇ 0.2°; or a diffraction peak at 15.2 ⁇ 0.2°; or a diffraction peak at 9.9 ⁇ 0.2°; or a diffraction peak at 16.7 ⁇ 0.2° or a diffraction peak at 18.2 ⁇ 0.2°; or a diffraction peak at 17.9 ⁇ 0.2°; or a diffraction peak at 25.5 ⁇ 0.2°; or a diffraction peak at 15.0 ⁇ 0.2°; or Has a diffraction peak at 19.5 ⁇ 0.2°; or has a diffraction peak at 23.6 ⁇ 0.2°; preferably includes any 2-5, or 3-5, or 3-6, or 3- 8 places, or 5-8 places, or 6-8 places; more preferably including any 6 places, 7 places or 8 places;
- the X-ray powder diffraction pattern of Form III contains at least one or more diffraction peaks located at 2 ⁇ of 4.6 ⁇ 0.2°, 15.2 ⁇ 0.2° or 9.9 ⁇ 0.2°, preferably 2 of them, more preferably 3 of them Optionally, it may further comprise at least one of 2 ⁇ being 16.7 ⁇ 0.2°, 18.2 ⁇ 0.2°, 17.9 ⁇ 0.2°, 25.5 ⁇ 0.2° or 15.0 ⁇ 0.2°, preferably including 2, 3, 4 or 5;
- diffraction peaks located at 2 ⁇ of 4.6 ⁇ 0.2°, 15.2 ⁇ 0.2°, 9.9 ⁇ 0.2°, 16.7 ⁇ 0.2°, 18.2 ⁇ 0.2° and 17.9 ⁇ 0.2°;
- diffraction peaks located at 2 ⁇ of 4.6 ⁇ 0.2°, 15.2 ⁇ 0.2°, 9.9 ⁇ 0.2°, 16.7 ⁇ 0.2°, 18.2 ⁇ 0.2° and 15.0 ⁇ 0.2°;
- the X-ray powder diffraction pattern of Form III optionally further comprises positions at 2 ⁇ of 19.5 ⁇ 0.2°, 23.6 ⁇ 0.2°, 26.1 ⁇ 0.2°, 22.0 ⁇ 0.2°, 20.2 ⁇ 0.2°, 21.1 ⁇ 0.2° or 27.4 ⁇ 0.2 one or more diffraction peaks; preferably at least include any 2-3, or 4-5, or 6-7; more preferably, include any 2, 3, 4, 5, 6, 7;
- the X-ray powder diffraction pattern of Form III contains 4.6 ⁇ 0.2°, 15.2 ⁇ 0.2°, 9.9 ⁇ 0.2°, 16.7 ⁇ 0.2°, 18.2 ⁇ 0.2°, 17.9 ⁇ 0.2°, 25.5 ⁇ 0.2° at 2 ⁇ at 2 ⁇ , 15.0 ⁇ 0.2°, 19.5 ⁇ 0.2°, 23.6 ⁇ 0.2°, 26.1 ⁇ 0.2°, 22.0 ⁇ 0.2°, 20.2 ⁇ 0.2°, 21.1 ⁇ 0.2° or 27.4 ⁇ 0.2 one or more diffraction peaks; preferably , comprising diffraction peaks at optional 4, 5, 6, 8 or 10 locations;
- the X-ray powder diffraction pattern of Form III has diffraction peaks at the following positions at 2 ⁇ :
- Example 63 of the present invention 6-(((R)-2-hydroxy-2-methylbut-3-yn-1-yl)oxy)-4-(6-(6-((6- Methoxypyridin-3-yl)methyl)-3,6diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-
- the X-ray powder diffraction pattern of 3-carbonitrile crystal form III is basically shown in FIG. 7 ;
- the DSC pattern is basically shown in FIG. 8 ;
- the TGA pattern is basically shown in FIG. 9 .
- the compound shown in Example 63 is 6-((((R)-2-hydroxy-2-methylbut-3-yn-1-yl)oxy)-4-(6 -(6-((6-Methoxypyridin-3-yl)methyl)-3,6diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[ 1,5-a]pyridine-3-carbonitrile crystal form IV.
- the X-ray powder diffraction pattern of Form IV has a diffraction peak at 2 ⁇ of 5.0 ⁇ 0.2°; or a diffraction peak at 4.8 ⁇ 0.2°; or a diffraction peak at 15.0 ⁇ 0.2°; or a diffraction peak at 19.1 ⁇ 0.2° or a diffraction peak at 14.3 ⁇ 0.2°; or a diffraction peak at 10.0 ⁇ 0.2°; or a diffraction peak at 23.9 ⁇ 0.2°; or a diffraction peak at 25.1 ⁇ 0.2°; or Has a diffraction peak at 30.3 ⁇ 0.2°; or has a diffraction peak at 9.6 ⁇ 0.2°; preferably includes any 2-5, or 3-5, or 3-6, or 3- 8 places, or 5-8 places, or 6-8 places; more preferably including any 6 places, 7 places or 8 places;
- the X-ray powder diffraction pattern of crystal form IV contains at least one or more diffraction peaks located at 2 ⁇ of 5.0 ⁇ 0.2°, 4.8 ⁇ 0.2° or 15.0 ⁇ 0.2°, preferably 2 of them, more preferably 3 of them Optionally, it may further comprise at least one of 2 ⁇ being 19.1 ⁇ 0.2°, 14.3 ⁇ 0.2°, 10.0 ⁇ 0.2°, 23.9 ⁇ 0.2° or 25.1 ⁇ 0.2°, preferably including 2, 3, 4 or 5;
- diffraction peaks located at 2 ⁇ of 5.0 ⁇ 0.2°, 4.8 ⁇ 0.2°, 15.0 ⁇ 0.2°, 19.1 ⁇ 0.2°, 14.3 ⁇ 0.2° and 10.0 ⁇ 0.2°;
- diffraction peaks located at 2 ⁇ of 5.0 ⁇ 0.2°, 4.8 ⁇ 0.2°, 15.0 ⁇ 0.2°, 19.1 ⁇ 0.2°, 14.3 ⁇ 0.2° and 23.9 ⁇ 0.2°;
- the X-ray powder diffraction pattern of the crystal form IV optionally further comprises one or more diffraction peaks located at 2 ⁇ of 30.3 ⁇ 0.2° or 9.6 ⁇ 0.2°; preferably at least any of 2-3, or 4-5 place, or 6-7 places; further preferably, including any 2 places, 3 places, 4 places, 5 places, 6 places, 7 places;
- the X-ray powder diffraction pattern of Form IV contains 5.0 ⁇ 0.2°, 4.8 ⁇ 0.2°, 15.0 ⁇ 0.2°, 19.1 ⁇ 0.2°, 14.3 ⁇ 0.2°, 10.0 ⁇ 0.2°, 23.9 ⁇ 0.2° at 2 ⁇ at 2 ⁇
- the X-ray powder diffraction pattern of Form IV has diffraction peaks at the following positions at 2 ⁇ :
- Example 63 of the present invention 6-(((R)-2-hydroxy-2-methylbut-3-yn-1-yl)oxy)-4-(6-(6-((6- Methoxypyridin-3-yl)methyl)-3,6diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-
- the X-ray powder diffraction pattern of 3-carbonitrile crystal form IV is basically shown in Figure 10; its DSC pattern is basically shown in Figure 11; its TGA pattern is basically shown in Figure 12.
- the compound shown in Example 63 is 6-((((R)-2-hydroxy-2-methylbut-3-yn-1-yl)oxy)-4-(6 -(6-((6-Methoxypyridin-3-yl)methyl)-3,6diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[ 1,5-a]pyridine-3-carbonitrile Form V.
- the X-ray powder diffraction pattern of Form V has a diffraction peak at 2 ⁇ of 4.7 ⁇ 0.2°; or a diffraction peak at 18.2 ⁇ 0.2°; or a diffraction peak at 10.1 ⁇ 0.2°; or a diffraction peak at 18.8 ⁇ 0.2° or a diffraction peak at 15.6 ⁇ 0.2°; or a diffraction peak at 17.0 ⁇ 0.2°; or a diffraction peak at 21.8 ⁇ 0.2°; or a diffraction peak at 14.7 ⁇ 0.2°; or Has a diffraction peak at 19.3 ⁇ 0.2°; or has a diffraction peak at 25.8 ⁇ 0.2°; preferably includes any 2-5, or 3-5, or 3-6, or 3- 8, or 5-8, or 6-8; more preferably including any 6, 7 or 8 of them.
- the X-ray powder diffraction pattern of the crystal form V contains at least one or more diffraction peaks located at 2 ⁇ of 4.7 ⁇ 0.2°, 18.2 ⁇ 0.2° or 10.1 ⁇ 0.2°, preferably 2 of them, more preferably 3 of them
- it may further comprise at least one of 2 ⁇ being 18.8 ⁇ 0.2°, 15.6 ⁇ 0.2°, 17.0 ⁇ 0.2°, 21.8 ⁇ 0.2° or 14.7 ⁇ 0.2°, preferably including 2, 3, 4 or 5;
- diffraction peaks located at 2 ⁇ of 4.7 ⁇ 0.2°, 18.2 ⁇ 0.2°, 10.1 ⁇ 0.2°, 18.8 ⁇ 0.2, 15.6 ⁇ 0.2° and 21.8 ⁇ 0.2°;
- diffraction peaks located at 2 ⁇ of 4.7 ⁇ 0.2°, 18.2 ⁇ 0.2°, 10.1 ⁇ 0.2°, 18.8 ⁇ 0.2, 15.6 ⁇ 0.2° and 14.7 ⁇ 0.2° are included.
- the X-ray powder diffraction pattern of Form V optionally further comprises positions at 2 ⁇ of 19.3 ⁇ 0.2°, 25.8 ⁇ 0.2°, 15.2 ⁇ 0.2°, 17.8 ⁇ 0.2°, 20.4 ⁇ 0.2°, 23.5 ⁇ 0.2° or 25.6 ⁇ 0.2°
- diffraction peaks located at 4.7 ⁇ 0.2°, 18.2 ⁇ 0.2°, 10.1 ⁇ 0.2°, 18.8 ⁇ 0.2°, 15.6 ⁇ 0.2°, 17.0 ⁇ 0.2°, 19.3 ⁇ 0.2°, and 15.2 ⁇ 0.2°.
- the X-ray powder diffraction pattern of Form V contains 2 ⁇ at 4.7 ⁇ 0.2°, 18.2 ⁇ 0.2°, 10.1 ⁇ 0.2°, 18.8 ⁇ 0.2°, 15.6 ⁇ 0.2°, 17.0 ⁇ 0.2°, 21.8 ⁇ 0.2°, 14.7
- the X-ray powder diffraction pattern of Form V has diffraction peaks at the following positions at 2 ⁇ :
- diffraction peaks located at 2 ⁇ of 4.7 ⁇ 0.2°, 10.1 ⁇ 0.2°, 18.8 ⁇ 0.2°, 15.6 ⁇ 0.2°, 17.0 ⁇ 0.2° and 21.8 ⁇ 0.2°;
- Example 63 of the present invention 6-(((R)-2-hydroxy-2-methylbut-3-yn-1-yl)oxy)-4-(6-(6-((6- Methoxypyridin-3-yl)methyl)-3,6diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-
- the X-ray powder diffraction pattern of 3-carbonitrile crystal form V is basically shown in Figure 13; its DSC pattern is basically shown in Figure 14; its TGA pattern is basically shown in Figure 15.
- the crystal form of the present invention is characterized in that the 2 ⁇ error between the positions of the diffraction peaks whose relative peak intensity is the top ten in the X-ray powder diffraction pattern and the diffraction peaks at the corresponding positions in the corresponding drawings is ⁇ 0.2° ⁇ 0.5° , preferably ⁇ 0.2° ⁇ 0.3°, most preferably ⁇ 0.2°.
- the crystal form of any compound described in the general formula (I) is a solvent-containing or solvent-free crystal form, wherein the solvent is selected from water, methanol, acetone, ethyl acetate, Acetonitrile, ethanol, 88% acetone, tetrahydrofuran, 2-methyl-tetrahydrofuran, dichloromethane, 1,4-dioxane, benzene, toluene, isopropanol, n-butanol, isobutanol, N,N- Dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidone, dimethylsulfoxide, n-propanol, tert-butanol, 2-butanone, 3-pentanone, n-heptane, One or more of heptane, ethyl formate, isopropyl acetate, cyclohexane,
- the number of solvents is 0.2-3, preferably 0.2, 0.5, 1, 1.5, 2, 2.5 or 3, more preferably 0.5, 1, 2 or 3.
- the crystalline form of the compound of formula (I) is a non-solvent crystalline form, preferably an anhydrous crystalline form.
- the crystal form of the compound of general formula (I) is a hydrate crystal form, and the number of water is 0.2-3, preferably 0.2, 0.5, 1, 1.5, 2, 2.5 or 3, More preferably 0.5, 1, 2 or 3.
- the crystal form of ]pyridine-3-carbonitrile is a nonsolvent compound, preferably an anhydrate or a hydrate.
- the number of water in the hydrate crystal form of pyridine-3-carbonitrile is 0.2-3, preferably 0.2, 0.5, 1, 1.5, 2, 2.5 or 3, more preferably 0.5, 1, 2 or 3.
- XRPD may have certain displacement and intensity deviations due to detection methods, conditions and instrumentation.
- its XRPD is shown in spectrum X, but those of ordinary skill know that when the key characteristic peak shift 2 ⁇ deviation is ⁇ 0.5, especially when it is about ⁇ 0.2, it can be regarded as the same crystal form.
- the present invention also provides a method for preparing the crystal form of the compound represented by the general formula (I), which specifically comprises the following steps:
- the suspension density is preferably 50-200 mg/mL
- Poor solvents are selected from methanol, acetone, ethyl acetate, tetrahydrofuran, acetonitrile, ethanol, 88% acetone, 2-methyl-tetrahydrofuran, dichloromethane, 1,4-dioxane, methyl tert-butyl ether, n-heptane, benzene, toluene, chlorobenzene, isopropanol, n-butanol, isobutanol, N,N-dimethylformamide, N,N-dimethylacetamide, dimethyl sulfoxide, n- Propanol, ethyl formate, isopropyl acetate, tert-butanol, 2-butanone or 3-pentanone; preferably acetonitrile, acetone, ethyl acetate, methanol, ethanol.
- the present invention also provides a method for preparing the crystal form of the compound represented by the general formula (I), which specifically comprises the following steps:
- Benign solvent selected from methanol, acetone, ethyl acetate, tetrahydrofuran, acetonitrile, ethanol, 88% acetone, 2-methyl-tetrahydrofuran, dichloromethane, 1,4-dioxane, benzene, toluene, chlorobenzene, iso Propanol, n-butanol, isobutanol, N,N-dimethylformamide, N,N-dimethylacetamide, dimethyl sulfoxide, n-propanol, ethyl formate, isopropyl acetate, tert-butanol, 2-butanone or 3-pentanone; preferably dichloromethane, tetrahydrofuran, 2-methyl-tetrahydrofuran, 1,4-dioxane, dimethylsulfoxide, acetonitrile, 2-butanone.
- the poor solvent is selected from methanol, ethanol, ethyl acetate, acetone, isopropanol, toluene, n-heptane, water, isopropyl acetate, cyclohexane, methyl tert-butyl ether, isopropyl ether; preferably water, n-heptane Heptane, cyclohexane and methyl tert-butyl ether.
- Another object of the present invention is to provide a pharmaceutical composition, which contains a therapeutically effective amount of the crystalline form of the compound represented by formula (I), and one or more pharmaceutically acceptable carriers or excipients.
- Another object of the present invention is to provide a compound of the general formula (I), 6-(((R)-2-hydroxy-2-methylbut-3-yn-1-yl)oxy)-4-(6 -(6-((6-Methoxypyridin-3-yl)methyl)-3,6diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[ The crystal form of 1,5-a]pyridine-3-carbonitrile and the application of its pharmaceutical composition in the preparation of RET inhibitor medicine.
- the object of the present invention is to provide the crystal form of the compound represented by the general formula (I) and the application of the pharmaceutical composition in the preparation of a drug for the treatment and/or prevention of tumors.
- the tumor is selected from non-small cell lung cancer, fibrous Sarcomas, pancreatic tumors, medullary thyroid carcinomas, papillary thyroid tumors, soft tissue sarcomas, high-grade solid tumors, breast tumors, and colon tumors.
- the crystal form can be identified by powder X-ray diffraction.
- powder X-ray diffraction peak intensities and/or peak profiles may vary due to different experimental conditions, such as different diffraction test conditions and/or preferred orientations, etc.
- the measured 2 ⁇ value will have an error of about ⁇ 0.2, and individual peaks may have an error of about ⁇ 0.3 or ⁇ 0.4.
- the relative intensity values of the peaks are more dependent on certain properties of the sample being measured than the position of the peaks, such as the size of the crystals in the sample, the orientation of the crystals and the purity of the material being analysed, and therefore the peaks displayed Intensity deviations in the range of about ⁇ 20% or more are possible.
- alkyl refers to a saturated aliphatic hydrocarbon group, which is a straight or branched chain group containing 1 to 20 carbon atoms, preferably an alkyl group containing 1 to 8 carbon atoms, more preferably 1 to 6 carbon atoms , most preferably an alkyl group of 1 to 3 carbon atoms.
- Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1 ,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2- Methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3 -Dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2 -Methylhexyl, 3-methylhexyl, 4-methylhe
- lower alkyl groups containing 1 to 6 carbon atoms include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl base, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-Methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylpropyl butyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl base, 2,3-dimethylbutyl, etc.
- Alkyl groups may be substituted or unsubstituted, and when substituted, the substituents may be substituted at any available point of attachment, and the substituents are preferably one or more of the following groups independently selected from alkyl, Alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy , heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, oxo, carboxyl or carboxylate, the present invention is preferably methyl, ethyl, isopropyl, tert-butyl, haloalkyl, deuterium substituted alkyl, alkoxy substituted alkyl and hydroxy substituted alkyl.
- cycloalkyl refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent, the cycloalkyl ring containing 3 to 20 carbon atoms, preferably 3 to 12 carbon atoms, more preferably 3 to 8 carbon atoms carbon atoms, most preferably 3 to 6 carbon atoms.
- Non-limiting examples of monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatriene
- Polycyclic cycloalkyl groups include spiro, fused and bridged cycloalkyl groups, preferably cyclopropyl, cyclobutyl, cyclohexyl, cyclopentyl and cycloheptyl.
- heterocyclyl refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent containing from 3 to 20 ring atoms, one or more of which is selected from nitrogen, oxygen or S(O) m (where m is an integer from 0 to 2) heteroatoms, excluding ring moieties of -OO-, -OS- or -SS-, the remaining ring atoms being carbon.
- ring atoms excluding ring moieties of -OO-, -OS- or -SS-, the remaining ring atoms being carbon.
- it contains 3 to 12 ring atoms, of which 1 to 4 are heteroatoms; more preferably 3 to 8 ring atoms; most preferably 3 to 6 ring atoms.
- Non-limiting examples of monocyclic heterocyclyl groups include oxetanyl, thietanyl, pyrrolidinyl, pyrrolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothienyl, dihydroimidazolyl, dihydroimidazolyl Hydrofuranyl, dihydropyrazolyl, dihydropyrrolyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, pyranyl, etc., preferably oxetanyl , pyrrolidone, tetrahydrofuranyl, pyrazolidine, morpholinyl, piperazinyl and pyranyl.
- Polycyclic heterocyclic groups include spiro, condensed and bridged heterocyclic groups; the spiro, condensed and bridged heterocyclic groups are optionally connected with other groups through a single bond, or through a ring Any two or more atoms above are further cyclo-linked to other cycloalkyl, heterocyclyl, aryl and heteroaryl groups.
- Heterocyclyl may be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkane Thio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio , heterocycloalkylthio, oxo, carboxyl or carboxylate.
- the substituents are preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkane Thio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl,
- Haloalkyl refers to an alkyl group substituted with one or more halogens, wherein alkyl is as defined above.
- Haloalkoxy refers to an alkoxy group substituted with one or more halogens, wherein alkoxy is as defined above.
- Hydroalkyl refers to an alkyl group substituted with hydroxy, wherein alkyl is as defined above.
- Alkenyl refers to an alkenyl group, also known as an alkenyl group, wherein the alkenyl group may be further substituted with other related groups such as: alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen , mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, carboxyl or carboxylate.
- Alkynyl refers to (CH ⁇ C-), wherein the alkynyl group may be further substituted with other related groups such as: alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto , hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, carboxyl or carboxyl acid group.
- Halogen refers to fluorine, chlorine, bromine or iodine.
- Amino refers to -NH2 .
- Cyano refers to -CN.
- Niro refers to -NO2 .
- Carboxyl refers to -C(O)OH.
- THF tetrahydrofuran
- EtOAc refers to ethyl acetate
- MeOH refers to methanol
- DMF N,N-dimethylformamide
- DIPEA diisopropylethylamine
- TFA trifluoroacetic acid
- MeCN refers to acetonitrile
- DMA refers to N,N-dimethylacetamide.
- Et2O refers to diethyl ether.
- DCE 1,2 dichloroethane
- DIPEA N,N-diisopropylethylamine
- NBS N-bromosuccinimide
- NIS N-iodosuccinimide
- Cbz-Cl refers to benzyl chloroformate
- Pd2(dba )3 refers to tris(dibenzylideneacetone)dipalladium.
- Dppf refers to 1,1'-bisdiphenylphosphinoferrocene.
- HATU refers to 2-(7-benzotriazole oxide)-N,N,N',N'-tetramethylurea hexafluorophosphate.
- KHMDS refers to potassium hexamethyldisilazide
- LiHMDS refers to lithium bistrimethylsilylamide.
- MeLi refers to methyl lithium
- n-BuLi refers to n-butyllithium
- NaBH(OAc) 3 refers to sodium triacetoxyborohydride.
- DMAP refers to 4-dimethylaminopyridine.
- SEM-Cl refers to chloromethyltrimethylsilyl ethyl ether.
- Xantphos refers to 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene.
- DCM dichloromethane
- X is selected from A, B, or C
- X is selected from A, B and C
- X is A, B or C
- X is A, B and C
- X is A, B and C
- the hydrogen atom of the present invention can be substituted by its isotope deuterium, and any hydrogen atom in the embodiment compounds involved in the present invention can also be substituted by deuterium atom.
- heterocyclic group optionally substituted with alkyl means that an alkyl group may, but need not, be present, and the description includes the case where the heterocyclic group is substituted with an alkyl group and the case where the heterocyclic group is not substituted with an alkyl group .
- Substituted means that one or more hydrogen atoms in a group, preferably up to 5, more preferably 1 to 3 hydrogen atoms, independently of each other, are substituted by the corresponding number of substituents. It goes without saying that the substituents are only in their possible chemical positions, and the person skilled in the art can determine (either experimentally or theoretically) possible or impossible substitutions without undue effort. For example, amino or hydroxyl groups with free hydrogens may be unstable when combined with carbon atoms with unsaturated (eg, olefinic) bonds.
- “Pharmaceutical composition” means a mixture containing one or more of the compounds described herein, or a physiologically/pharmaceutically acceptable salt or prodrug thereof, with other chemical components, and other components such as a physiological/pharmaceutically acceptable carrier and excipients.
- the purpose of the pharmaceutical composition is to facilitate the administration to the organism, facilitate the absorption of the active ingredient and then exert the biological activity.
- “Pharmaceutically acceptable salts” refers to salts of the compounds of the present invention, which are safe and effective when used in mammals, and have the desired biological activity.
- Figure 1 is 6-(((R)-2-hydroxy-2-methylbut-3-yn-1-yl)oxy)-4-(6-(6-((6-methoxypyridine- 3-yl)methyl)-3,6diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile crystal XRPD representation of Type I.
- Figure 2 is 6-(((R)-2-hydroxy-2-methylbut-3-yn-1-yl)oxy)-4-(6-(6-((6-methoxypyridine- 3-yl)methyl)-3,6diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile crystal DSC diagram of Form I.
- Figure 3 is 6-(((R)-2-hydroxy-2-methylbut-3-yn-1-yl)oxy)-4-(6-(6-((6-methoxypyridine- 3-yl)methyl)-3,6diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile crystal Schematic representation of the TGA of Type I.
- Figure 4 is 6-(((R)-2-hydroxy-2-methylbut-3-yn-1-yl)oxy)-4-(6-(6-((6-methoxypyridine- 3-yl)methyl)-3,6diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile crystal XRPD representation of Type II.
- Figure 5 is 6-(((R)-2-hydroxy-2-methylbut-3-yn-1-yl)oxy)-4-(6-(6-((6-methoxypyridine- 3-yl)methyl)-3,6diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile crystal DSC diagram of Form II.
- Figure 6 is 6-(((R)-2-hydroxy-2-methylbut-3-yn-1-yl)oxy)-4-(6-(6-((6-methoxypyridine- 3-yl)methyl)-3,6diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile crystal Schematic representation of the TGA of Type II.
- Figure 7 is 6-(((R)-2-hydroxy-2-methylbut-3-yn-1-yl)oxy)-4-(6-(6-((6-methoxypyridine- 3-yl)methyl)-3,6diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile crystal XRPD representation of Type III.
- Figure 8 is 6-(((R)-2-hydroxy-2-methylbut-3-yn-1-yl)oxy)-4-(6-(6-((6-methoxypyridine- 3-yl)methyl)-3,6diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile crystal DSC diagram of Form III.
- Figure 9 is 6-(((R)-2-hydroxy-2-methylbut-3-yn-1-yl)oxy)-4-(6-(6-((6-methoxypyridine- 3-yl)methyl)-3,6diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile crystal Schematic representation of the TGA of Type III.
- Figure 10 is 6-(((R)-2-hydroxy-2-methylbut-3-yn-1-yl)oxy)-4-(6-(6-((6-methoxypyridine- 3-yl)methyl)-3,6diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile crystal XRPD representation of type IV.
- Figure 11 is 6-(((R)-2-hydroxy-2-methylbut-3-yn-1-yl)oxy)-4-(6-(6-((6-methoxypyridine- 3-yl)methyl)-3,6diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile crystal DSC diagram of Form IV.
- Figure 12 is 6-(((R)-2-hydroxy-2-methylbut-3-yn-1-yl)oxy)-4-(6-(6-((6-methoxypyridine- 3-yl)methyl)-3,6diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile crystal TGA diagram of type IV.
- Figure 13 is 6-(((R)-2-hydroxy-2-methylbut-3-yn-1-yl)oxy)-4-(6-(6-((6-methoxypyridine- 3-yl)methyl)-3,6diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile crystal XRPD illustration of Type V.
- Figure 14 is 6-(((R)-2-hydroxy-2-methylbut-3-yn-1-yl)oxy)-4-(6-(6-((6-methoxypyridine- 3-yl)methyl)-3,6diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile crystal DSC illustration of Type V.
- Figure 15 is 6-(((R)-2-hydroxy-2-methylbut-3-yn-1-yl)oxy)-4-(6-(6-((6-methoxypyridine- 3-yl)methyl)-3,6diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile crystal TGA illustration of Type V.
- Figure 16 is 6-(((R)-2-hydroxy-2-methylbut-3-yn-1-yl)oxy)-4-(6-(6-((6-methoxypyridine- 3-yl)methyl)-3,6diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile crystal DVS illustration of Type I.
- the structures of the compounds of the present invention are determined by nuclear magnetic resonance (NMR) or/and liquid chromatography-mass spectrometry (LC-MS). NMR chemical shifts ([delta]) are given in parts per million (ppm). NMR was measured by Bruker AVANCE-400 nuclear magnetic instrument, and the solvent was deuterated dimethyl sulfoxide (DMSO-d 6 ), deuterated methanol (CD 3 OD) and deuterated chloroform (CDCl 3 ), and the internal standard was four Methylsilane (TMS).
- DMSO-d 6 dimethyl sulfoxide
- CD 3 OD deuterated methanol
- CDCl 3 deuterated chloroform
- TMS Methylsilane
- the thin layer chromatography silica gel plate uses Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plate, the specifications used for TLC are 0.15mm ⁇ 0.20mm, and the specifications used for TLC separation and purification products are 0.4mm ⁇ 0.5mm.
- Column chromatography generally uses 200-300 mesh Yantai Huanghai silica gel as the carrier.
- the starting materials in the examples of the present invention are known and commercially available, or can be synthesized using methods known in the art.
- the third step 4-bromo-6-(2-(methylsulfinyl ⁇ sulfinyl>)ethoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile
- 5-Bromo-2-fluoropyridine 500 mg, 2.5 mmol was dissolved in 20 mL of DMSO, and tert-butyl 3,6-diazabicyclo[3.1.1]heptane-6-carboxylate (489 mg) was added. , 2.8 mmol), potassium carbonate (1.7 g, 12.5 mmol), and stirred at 90 °C overnight.
- Step 6 3-(5-Bromopyridin-2-yl)-6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1] Heptane
- the seventh step 6-(2-(methylsulfinyl ⁇ sulfinyl>)ethoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborone) Pentacyclo-2-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
- Step 8 4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptane-3-yl) Pyridin-3-yl)-6-(2-(methylsulfinyl ⁇ sulfinyl>)ethoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile
- Step 2 6-Bromo-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptane- 3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
- the third step 6-(3-(2-hydroxypropan-2-yl)azetidin-1-yl)-4-(6-(6-((6-methoxypyridin-3-yl)methane yl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
- the second step 6-(3-hydroxy-3-methylbut-1-yn-1-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborone Pentacyclo-2-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
- the third step 6-(3-hydroxy-3-methylbut-1-yn-1-yl)-4-(6-(6-((6-methoxypyridin-3-yl)methyl) -3,6-Diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
- the first step 4-bromo-6-(2-cyano-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile
- reaction solution was concentrated, dissolved in ethyl acetate (10 mL), washed with water three times (5 mL*3), and the organic phase was concentrated and purified by column chromatography (dichloromethane/methanol: 30/1) to obtain the product 4-bromo-6- (2-cyano-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile (180 mg, yellow solid, 67.1% yield).
- the second step 6-(2-cyano-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6- Diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
- the first step 3-bromo-5-(2-(methylsulfonyl)ethyl)pyridine
- the third step 6-(2-(methylsulfonyl)ethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Azolo[1,5-a]pyridine-3-carbonitrile
- the fourth step 4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptane-3-yl) Pyridin-3-yl)-6-(2-(methylsulfonyl)ethyl)pyrazolo[1,5-a]pyridine-3-carbonitrile
- the third step 4-bromo-6-((1-hydroxythibutan-3-yl)methoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile
- the fourth step 4-bromo-6-((1-imino-1-hydroxy-116-thibutan-3-yl)methoxy)pyrazolo[1,5-a]pyridine-3-methyl Nitrile
- the fifth step 6-((1-imino-1-hydroxy-1l6-thibutan-3-yl)methoxy)-4-(4,4,5,5-tetramethyl-1,3 ,2-Dioxaborolane-2-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
- the seventh step of reference example 1 obtains 6-((1-imino-1-hydroxy-116-thibutan-3-yl)methoxy)-4-(4,4,5,5-tetramethyl) -1,3,2-Dioxaborolan-2-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (96 mg, white solid, 64%).
- the sixth step 6-((1-imino-1-hydroxy-1l6-thibutan-3-yl)methoxy)-4-(6-(6-((6-methoxypyridine-3 -yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
- reference example 12 obtained 4-(6-(6-((6-methoxypyridin-3-yl) Methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-6-(2-(1-hydroxytetrahydro-2H-thiopyran-4) -yl)ethoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile (29 mg, white solid).
- the first step Preparation of 4-bromo-6-((tetrahydro-2H-thiopyran-4-yl)oxo)pyrazolo[1,5-a]pyridine-3-carbonitrile
- the second step 4-bromo-6-((1-imino-1-hydroxyhexahydro-116-thiopyran-4-yl)oxo)pyrazolo[1,5-a]pyridine-3-methyl Preparation of Nitriles
- the third step 6-((1-imino-1-hydroxyhexahydro-116-thiopyran-4-yl)oxo)-4-(6-(6-((6-methoxypyridine-3 -yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile preparation
- Reference Example 7 obtained 6-(3-amino-3-methylbut-1-yn-1-yl)-4-(6-(6 -((6-Methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1 ,5-a]pyridine-3-carbonitrile.
- 6-Bromo-4-hydroxypyrazolo[1,5-a]pyridine-3-carbonitrile (5 g, 21 mmol) and triethylamine (4.2 g, 42 mmol) were dissolved in dichloromethane (500 mL) over ice Trifluoromethanesulfonic anhydride (8.9 g, 31.5 mmol) was added under the bath, then stirred at room temperature for 12 hours, added with 100 mL of water, and extracted with ethyl acetate (80 mL*3). The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and spin-dried.
- the third step tert-butyl 3-(5-(6-bromo-3-cyanopyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)-3,6-di Azabicyclo[3.1.1]heptane-6-carboxylate
- the fourth step 4-(6-(3,6-diazabicyclo[3.1.1]heptane-3-yl)pyridin-3-yl)-6-bromopyrazolo[1,5-a ]pyridine-3-carbonitrile
- the fifth step 6-bromo-4-(6-(6-((5-fluoro-6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1 ]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
- Step 6 4-(6-(6-((5-Fluoro-6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptane- 3-yl)pyridin-3-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
- 6-Bromo-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl )pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile 50 mg, 0.1 mmol
- N,N-dimethylformamide (2 mL) 1-cyclopropane was added Prop-2-yn-1-ol (47 mg, 0.5 mmol), triethylamine (50 mg, 0.5 mmol), Pd 2 (PPh 3 ) 2 Cl 2 (7 mg, 0.01 mmol), CuI (1 mg, 0.01 mmol) , and reacted overnight at 65°C under nitrogen protection.
- the first step 6-bromo-4-(6-(6-((6-(methoxy-d3)pyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1 ]Heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile preparation
- Step 2 6-(3-Amino-3-methylbut-1-yn-1-yl)-4-(6-(6-((6-(methoxy-d3)pyridin-3-yl) ) methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile preparation
- the first step 5-(chloromethyl)-2-cyclopropoxypyridine
- Step 2 6-Bromo-4-(6-(6-((6-cyclopropoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptane -3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
- the third step 4-(6-(6-((6-cyclopropoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl )pyridin-3-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
- the first step 6-hydroxy-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptane- 3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
- the second step 6-((1-cyanocyclopropyl)methoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6- Diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
- Reference Example 1 sixth step to give 3-(5-bromopyridin-2-yl)-6-((6-(methoxy-d3)pyridin-3-yl)methyl)-3,6-diazabicyclo[3.1. 1] Heptane.
- Step 2 6-((6-(methoxy-d3)pyridin-3-yl)methyl)-3-(5-(4,4,5,5-tetramethyl-1,3,2 -Dioxaborolane-2-yl)pyridin-2-yl)-3,6-diazabicyclo[3.1.1]heptane
- the third step 6-hydroxy-4-(6-(6-((6-(methoxy-d3)pyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1 ]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
- 6-((6-(methoxy-d3)pyridin-3-yl)methyl)-3-(5-(4,4,5,5-tetramethyl-1,3,2-dioxane) Boran-2-yl)pyridin-2-yl)-3,6-diazabicyclo[3.1.1]heptane and 4-bromo-6-hydroxypyrazolo[1,5-a]pyridine -3-carbonitrile is the raw material Reference Example 1
- the eighth step obtains 6-hydroxy-4-(6-(6-((6-(methoxy-d3)pyridin-3-yl)methyl)-3, 6-Diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile.
- Step 4 6-((1-cyanocyclopropyl)methoxy)-4-(6-(6-((6-(methoxy-d3)pyridin-3-yl)methyl)- 3,6-Diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
- the second step is to obtain 6-((1-cyanocyclopropyl)methoxy)-4-(6-(6-((6-(methoxy-d3)pyridin-3-yl)methan yl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile.
- the first step 4-(6-(6-((5-fluoro-6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptane- 3-yl)pyridin-3-yl)-6-(3-(2-hydroxypropan-2-yl)azetidin-1-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
- the first step 6-bromo-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptane- 3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
- the first step was to obtain 6-(3-(2-hydroxypropane-2- yl)azetidin-1-yl)-4-(6-(6-((6-(methoxy-d3)pyridin-3-yl)methyl)-3,6-diazabicyclo[ 3.1.1] Heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (20 mg, yellow solid, 30%).
- the first step tert-butyl(3-cyano-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1 ]hept-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-6-yl)carbamate tert-butyl ester
- Step 2 6-amino-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptane- 3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
- the third step N-(3-cyano-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1 ]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-6-yl)-2-hydroxy-2-methylpropionamide
- the first step (1-(((3-cyano-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[ 3.1.1] Preparation of heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-6-yl)oxo)methyl)cyclopropyl)carbamate tert-butyl ester
- the second step 6-((1-aminocyclopropyl)methoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-di
- 6-((1-aminocyclopropyl)methoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-di Preparation of azabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
- the third step 6-((cis-3-hydroxy-3-methylcyclobutyl)methoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl) yl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
- the third step 6-((3-(hydroxymethyl)bicyclo[1.1.1]pentan-1-yl)methoxy)-4-(6-(6-((6-methoxypyridine) -3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3- Formonitrile
- the first step 6-((3-hydroxybicyclo[1.1.1]pentan-1-yl)methoxy)-4-(6-(6-((6-methoxypyridin-3-yl) )methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
- reference example 16 obtained 6-((1-imino-1-hydroxyhexahydro-116-thiopyran-4-yl)methoxy) -4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridine-3 -yl)pyrazolo[1,5-a]pyridine-3-carbonitrile.
- the second step 6-((1-cyano-3,3-difluorocyclobutyl)methoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl) yl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
- the first step 4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridine -3-yl)-6-(2-oxopropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile
- Step 2 6-((2-Hydroxy-2-methylbut-3-yn-1-yl)oxy)-4-(6-(6-((6-methoxypyridin-3-yl) )methyl)-3,6diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
- the first step 4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridine -3-yl)-6-(2-oxopropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile
- Step 2 6-((2-Hydroxy-2-methylbut-3-yn-1-yl)oxy)-4-(6-(6-((6-methoxypyridin-3-yl) )methyl)-3,6diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
- the third step 6-(((R)-2-hydroxy-2-methylbut-3-yn-1-yl)oxy)-4-(6-(6-((6-methoxypyridine) -3-yl)methyl)-3,6diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
- the first step 6-(((S)-2-hydroxy-2-methylbut-3-yn-1-yl)oxy)-4-(6-(6-((6-methoxypyridine) -3-yl)methyl)-3,6diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
- the first step 4-(6-(6-((5-fluoro-6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptane-3 -yl)pyridin-3-yl)-6-(2-oxopropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile
- Step 2 4-(6-(6-((5-Fluoro-6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptane-3 -yl)pyridin-3-yl)-6-(((S)-2-hydroxy-2-methylbut-3-yn-1-yl)oxy)pyrazolo[1,5-a]pyridine -3-carbonitrile
- Reference Example 31 The second step is to obtain 6-((3-cyano-3-methylcyclobutyl)methoxy)-4-(6-(6-((5-fluoro-6- Methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a] Pyridine-3-carbonitrile.
- the first step 1-cyano-N-(3-cyano-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo [3.1.1]Heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-6-yl)cyclopropane-1-carboxamide
- the first step 6-(3-cyano-3-methylazetidin-1-yl)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)- Preparation of 3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
- Reference Example 8 The second step obtained 6-((3-hydroxyoxetan-3-yl)ethynyl)-4-(6-(6-((6-methoxypyridin-3-yl)methyl) )-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (white solid).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
仪器 | CHIRALPAK IBN |
柱型 | 5.0cm I.D.×25cm L,10μm |
流动相 | Hexane/EtOH/DCM=60/30/10(V/V/V) |
流速 | 60mL/min |
检测波长 | UV 254nm |
柱温 | 35℃ |
仪器 | CHIRALPAK IBN |
柱型 | 5.0cm I.D.×25cm L,10μm |
流动相 | Hexane/EtOH/DCM=60/30/10(V/V/V) |
流速 | 60mL/min |
检测波长 | UV 254nm |
柱温 | 35℃ |
实施例编号 | RET IC 50(nM) | KDR IC 50(nM) | Ratio(KDR/RET) |
1 | 0.47 | 28 | 59 |
6 | 0.79 | 27.7 | 35 |
7 | 0.69 | 11 | 16 |
8 | 0.48 | 16 | 34 |
9 | 0.76 | 70.0 | 92 |
12 | 1.3 | 69 | 55 |
17 | 0.39 | 8.2 | 21 |
18 | 0.31 | 23 | 73 |
21 | 0.41 | 9.4 | 23 |
22 | 0.32 | 24 | 75 |
27 | 0.32 | 88 | 280 |
31 | 0.75 | 23 | 30 |
32 | 0.49 | 1.8 | 4 |
33 | 0.4 | 5.6 | 14 |
34 | 0.7 | 4.7 | 7 |
35 | 0.49 | 6.2 | 13 |
36 | 0.83 | 213.3 | 257 |
37 | 0.71 | 60.4 | 85 |
41 | 0.4 | 11 | 27 |
42 | 1.56 | 104.8 | 67 |
46 | 0.26 | 6.5 | 25 |
47 | 0.40 | 176 | 438 |
48 | 0.42 | 13 | 30 |
53 | 0.8 | 21.6 | 27 |
54 | 0.34 | 9 | 26 |
55 | 0.31 | 37.5 | 121 |
57 | 1.1 | 209.3 | 187 |
59 | 0.58 | 183.9 | 317 |
60 | 0.58 | 257.1 | 445 |
61 | 0.35 | 11.2 | 32 |
62 | 0.48 | 35.24 | 73 |
63 | 0.34 | 21.7 | 63 |
64 | 0.38 | 44.34 | 118 |
65 | 0.33 | 14.5 | 44 |
66 | 0.25 | 3.0 | 12 |
67 | 0.25 | 4.0 | 16 |
68 | 0.44 | 18.9 | 43 |
72 | 0.37 | 7.4 | 20 |
74 | 1.8 | 246.6 | 137 |
77 | 0.37 | 6.90 | 19 |
85 | 0.38 | 46 | 122 |
88 | 1.2 | 61 | 49 |
89 | 1.1 | 8.9 | 8 |
91 | 1.54 | 204.4 | 133 |
92 | 0.85 | 185.3 | 218 |
93 | 1.1 | 150.0 | 136 |
95 | 1.0 | 24 | 24 |
96 | 0.72 | 15.8 | 22 |
试剂 | 来源 | 批号 |
DMEM(高糖)培养液 | HyClone | AE29431648 |
胎牛血清(FBS) | gibco | 2148169CP |
青链霉素混合液 | gibco | 2145460 |
仪器型号 | SMS Intrinsic |
实验温度 | 25℃ |
干燥时间 | 0%RH 120min |
平衡dm/dt | 0.02%/min(最小10min,最大180min) |
RH(%)测量步长 | 10% |
测量梯度 | 0-95-0% |
循环次数 | 2 |
编号 | 媒介 | 晶型I溶解度(mg/mL) |
1 | pH 1 | >2.00 |
2 | pH 2 | >2.00 |
3 | pH 3 | 0.71 |
4 | pH 4 | 0.37 |
5 | pH 5 | 0.02 |
6 | pH 6 | 0.001 |
7 | FaSSGF | >2.00 |
8 | FaSSIF | 0.001 |
9 | FeSSIF | 0.09 |
溶剂 | 晶型I+II | 晶型I+III | 晶型I+IV | 晶型I+V |
乙酸乙酯 | I | I | I | I |
序号 | 溶剂 | 自由碱 |
- | 初始晶型 | 晶型I |
1 | 甲醇 | 晶型I |
2 | 乙醇 | 晶型II |
3 | 异丙醇 | 晶型I |
4 | 乙腈 | 晶型I |
5 | 丙酮 | 晶型III |
6 | 2-甲基-四氢呋喃 | 晶型II |
7 | 乙酸乙酯 | 晶型I |
8 | 甲苯 | 晶型I |
9 | 二丁酮 | 晶型III |
10 | 醋酸异丙酯 | 晶型I |
序号 | 溶剂 | 自由碱 |
- | 初始晶型 | 晶型I |
1 | 二氯甲烷 | 晶型I |
2 | 88%丙酮 | 晶型III |
3 | 丙酮 | 晶型III |
4 | 甲醇 | 晶型I |
序号 | 溶剂 | 自由碱 |
- | 初始晶型 | 晶型I |
1 | 二氯甲烷 | 晶型I |
2 | 88%丙酮 | 晶型IV |
3 | 丙酮 | 晶型I |
4 | 甲醇 | 晶型I |
5 | 2-甲基-四氢呋喃 | 晶型I |
6 | 三氯甲烷 | 晶型I |
Claims (19)
- 一种通式(I)所示化合物的晶型,其中:L选自-CH 2-或-NHC(O)-;M选自CR或N;R选自氢、氘、卤素、氨基、硝基、羟基、氰基、C 1-6烷基、C 1-6氘代烷基、C 1-6卤代烷基、C 1-6烷氧基、C 1-6氘代烷氧基、C 1-6卤代烷氧基、C 1-6羟烷基、C 2-6烯基、C 2-6炔基、C 3-8环烷基、3-8元杂环基、C 6-10芳基或5-12元杂芳基;X 1选自CR a或N;X 2选自CR b或N;R a和R b各自独立地选自氢、氘、卤素、氨基、硝基、羟基、氰基、C 1-6烷基、C 1-6氘代烷基、C 1-6卤代烷基、C 1-6烷氧基、C 1-6氘代烷氧基、C 1-6卤代烷氧基、C 1-6羟烷基、C 2- 6烯基、C 2-6炔基、C 3-8环烷基、3-8元杂环基、C 6-10芳基或5-12元杂芳基;R 1、R 2和R 3各自独立地选自氢、氘、卤素、氨基、硝基、羟基、氰基、C 1-6烷基、C 1-6氘代烷基、C 1-6卤代烷基、C 1-6烷氧基、C 1-6氘代烷氧基、C 1-6卤代烷氧基、C 1-6羟烷基、C 2-6烯基、C 2-6炔基、C 3-8环烷基、3-8元杂环基、C 6-10芳基或5-12元杂芳基;R 4选自C 2-6烯基、C 2-6炔基、3-8元杂环基、-O(CH 2) mR 5、-(CH 2) mR 5、-NR 6(CH 2) mR 5、-NR 6C(O)R 5、-CH=CH-(CH 2) mR 5、-O(CH 2) mS(O)R 5、-O(CH 2) mS(O) 2R 5或-O(CH 2) mS(O)(=NH)R 5,所述C 2-6烯基、C 2-6炔基和3-8元杂环基,任选地进一步被氘、卤素、氨基、硝基、羟基、氰基、C 1-6烷基、C 1-6氘代烷基、C 1-6卤代烷基、C 1-6烷氧基、C 1- 6氘代烷氧基、C 1-6卤代烷氧基、C 1-6羟烷基、C 2-6烯基、C 2-6炔基、C 3-8环烷基、3-12元杂环基、C 6-10芳基和5-12元杂芳基中的一个或多个取代基所取代;R 5和R 6各自独立地选自氢、氘、卤素、氨基、硝基、羟基、氰基、C 1-6烷基、C 1-6氘代烷基、C 1-6卤代烷基、C 1-6烷氧基、C 1-6氘代烷氧基、C 1-6卤代烷氧基、C 1-6羟烷基、C 2- 6烯基、C 2-6炔基、C 3-8环烷基、3-8元杂环基、C 6-10芳基或5-12元杂芳基,所述C 1-6烷基、C 1-6氘代烷基、C 1-6卤代烷基、C 1-6烷氧基、C 1-6氘代烷氧基、C 1-6卤代烷氧基、C 1-6羟烷基、C 2-6烯基、C 2-6炔基、C 3-8环烷基、3-8元杂环基、C 6-10芳基和5-12元杂芳基,任选地进一步被氘、卤素、氨基、硝基、羟基、氰基、氧代基、硫代基、C 1-6烷基、C 1-6氘代烷基、C 1-6卤代烷基、C 1-6烷氧基、C 1-6氘代烷氧基、C 1-6卤代烷氧基、C 1-6羟烷基、C 2-6烯基、C 2-6炔基、C 3-8环烷基、3-8元杂环基、C 6-10芳基、5-12元杂芳基、=NH、- (CH 2) tR 7、-(CH 2) tOR 7和-(CH 2) tC(O)NR 7R 8中的一个或多个取代基所取代;R 7和R 8各自独立地选自氢、氘、卤素、氨基、硝基、羟基、氰基、C 1-6烷基、C 1-6氘代烷基、C 1-6卤代烷基、C 1-6烷氧基、C 1-6氘代烷氧基、C 1-6卤代烷氧基、C 1-6羟烷基、C 2- 6烯基、C 2-6炔基、C 3-8环烷基、3-8元杂环基、C 6-10芳基或5-12元杂芳基,所述C 1-6烷基、C 1-6氘代烷基、C 1-6卤代烷基、C 1-6烷氧基、C 1-6氘代烷氧基、C 1-6卤代烷氧基、C 1-6羟烷基、C 2-6烯基、C 2-6炔基、C 3-8环烷基、3-8元杂环基、C 6-10芳基和5-12元杂芳基,任选地进一步被氘、卤素、氨基、硝基、羟基、氰基、C 1-6烷基、C 1-6氘代烷基、C 1-6卤代烷基、C 1-6烷氧基、C 1-6氘代烷氧基、C 1-6卤代烷氧基、C 1-6羟烷基、C 2-6烯基、C 2-6炔基、C 3-8环烷基、3-8元杂环基、C 6-10芳基和5-12元杂芳基中的一个或多个取代基所取代;n为0、1、2或3;m为0、1、2或3;且t为0、1、2或3。
- 根据权利要求1所述的化合物的晶型,其特征在于,M选自CR或N;R选自氢、氨基或C 1-3烷基,优选氢、氨基或甲基;X 1选自CR a或N;X 2选自CR b或N;R a和R b选自各自独立地选自氢、氘、卤素、C 1-3烷基或C 1-3烷氧基,优选氢、氟、氯、甲基或甲氧基;R 1、R 2和R 3各自独立地选自氢、氘、卤素、C 1-3烷基或C 1-3烷氧基,优选氢、氟、氯、甲基或甲氧基。
- 根据权利要求1-2中任一项所述的化合物的晶型,其特征在于,R 4选自C 2-3炔基、C 2-3烯基、3-8元含氮或氧原子的杂环基、-O(CH 2) mR 5、-(CH 2) mR 5、-NR 6(CH 2) mR 5、-NHC(O)R 5、-CH=CH-(CH 2) mR 5、-O(CH 2) mS(O)R 5、-O(CH 2) mS(O) 2R 5或-O(CH 2) mS(O)(=NH)R 5,3-8元含氮或氧原子的杂环基,任选地进一步被氘、氟、氯、溴、氨基、羟基、氰基、C 1-3烷基、C 1-3羟烷基或C 1-3烷氧基中的一个或多个取代基所取代;优选地,R 4选自乙烯基、乙炔基、氧杂环丁烷基、氮杂环丁烷基、吡咯烷基、哌啶基、2-氮杂螺[3.3]庚烷基、-OCH 2R 5、-O(CH 2) 2R 5、-(CH 2) 2R 5、-NR 6(CH 2) mR 5、-NHC(O)R 5、-CH=CH-(CH 2) mR 5、-O(CH 2) mS(O)R 5、-O(CH 2) mS(O) 2R 5或-O(CH 2) mS(O)(=NH)R 5,所述的乙烯基、乙炔基、氧杂环丁烷基、氮杂环丁烷基、吡咯烷基、哌啶基和2-氮杂螺[3.3]庚烷基,任选地进一步被氘、羟基、氰基、甲基、羟基乙基、2-羟基异丙基、2-氨基异丙基中的一个或多个取代基所取代;R 5选自氢、氘、卤素、氨基、硝基、羟基、氰基、C 1-3烷基、C 1-3氘代烷基、C 1-3卤代烷基、C 1-3烷氧基、C 1-3氘代烷氧基、C 1-3卤代烷氧基、C 1-3羟烷基、C 2-3烯基、C 2-3炔 基、C 3-6环烷基或3-8元杂环基,所述的C 1-3烷基、C 1-3氘代烷基、C 1-3卤代烷基、C 1-3烷氧基、C 1-3氘代烷氧基、C 1-3卤代烷氧基、C 1-3羟烷基、C 2-3烯基、C 2-3炔基、C 3-6环烷基和3-8元杂环基,任选地进一步被氘、卤素、氨基、硝基、羟基、氰基、C 1-3烷基、C 1-3氘代烷基、C 1-3卤代烷基、C 1-3烷氧基、C 1-3氘代烷氧基、C 1-3卤代烷氧基、C 1-3羟烷基、C 2-3烯基、C 2-3炔基、C 3-6环烷基、3-8元杂环基、-CH 2R 7、-CH 2OR 7和-C(O)NR 7R 8中的一个或多个取代基所取代;优选地,R 5选自甲基、乙基、异丙基、环丙基、环丁基、环戊基、乙炔基、氧杂环丁基、硫杂环丁基、氮杂环丁基、四氢吡喃基、双环[1.1.1]戊烷基或四氢-2H-硫代吡喃,任选地进一步被氘、羟基、氨基、氰基、氟、氯、溴、甲氧基、乙炔基、环丙基、羟乙基、氧代基、=NH、-CH 2OCH 3、-C(O)NH 2和-C(O)NHCH 3中的一个或多个取代基所取代;R 6选自氢、氘、卤素、氨基、羟基或C 1-3烷基,优选氢、氘或甲基;R 7和R 8各自独立地选自氢、氘、卤素、氨基、羟基或C 1-3烷基,优选氢、氘或甲基;n为0、1、2或3;且m为0、1、2或3。
- 根据权利要求1-5中任一项所述化合物的晶型,其特征在于,晶型为6-(((R)-2-羟基-2-甲基丁-3-炔-1-基)氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6二氮杂双环[3.1.1]庚烷-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈的晶型I、晶型II、晶型III、晶型IV或晶型V,其中:晶型I的X-射线粉末衍射图谱在2θ为5.0±0.2°处具有衍射峰;或者在9.6±0.2°处具有衍射峰;或者在15.0±0.2°处具有衍射峰;或者在17.2±0.2°处具有衍射峰;或者在 22.2±0.2°处具有衍射峰;或者在19.4±0.2°处具有衍射峰;或者在30.2±0.2°处具有衍射峰;或者在8.2±0.2°处具有衍射峰;或者在25.1±0.2°处具有衍射峰;或者在26.9±0.2°处具有衍射峰;优选包含上述衍射峰中的任意2-5处,或者3-5处,或者3-6处,或者3-8处,或者5-8处,或者6-8处;更优选包含其中任意6处、7处或8处;或晶型I的X-射线粉末衍射图谱在2θ为5.0±0.2°处具有衍射峰;或者在8.2±0.2°处具有衍射峰;或者在9.6±0.2°处具有衍射峰;或者在12.9±0.2°处具有衍射峰;或者在15.0±0.2°处具有衍射峰;或者在17.2±0.2°处具有衍射峰;或者在15.4±0.2°处具有衍射峰;或者在16.6±0.2°处具有衍射峰;或者在17.7±0.2°处具有衍射峰;或者在18.5±0.2°处具有衍射峰;优选包含上述衍射峰中的任意2-5处,或者3-5处,或者3-6处,或者3-8处,或者5-8处,或者6-8处;更优选包含其中任意6处、7处或8处;晶型II的X-射线粉末衍射图谱在2θ为4.8±0.2°处具有衍射峰;或者在17.7±0.2°处具有衍射峰;或者在16.6±0.2°处具有衍射峰;或者在9.4±0.2°处具有衍射峰;或者在18.4±0.2°处具有衍射峰;或者在19.1±0.2°处具有衍射峰;或者在17.0±0.2°处具有衍射峰;或者在18.6±0.2°处具有衍射峰;或者在4.5±0.2°处具有衍射峰;或者在15.4±0.2°处具有衍射峰;优选包含上述衍射峰中的任意2-5处,或者3-5处,或者3-6处,或者3-8处,或者5-8处,或者6-8处,更优选包含其中任意6处、7处或8处;晶型III的X-射线粉末衍射图谱在2θ为4.6±0.2°处具有衍射峰;或者在15.2±0.2°处具有衍射峰;或者在9.9±0.2°处具有衍射峰;或者在16.7±0.2°处具有衍射峰;或者在18.2±0.2°处具有衍射峰;或者在17.9±0.2°处具有衍射峰;或者在25.5±0.2°处具有衍射峰;或者在15.0±0.2°处具有衍射峰;或者在19.5±0.2°处具有衍射峰;或者在23.6±0.2°处具有衍射峰;优选包含上述衍射峰中的任意2-5处,或者3-5处,或者3-6处,或者3-8处,或者5-8处,或者6-8处;更优选包含其中任意6处、7处或8处;晶型IV的X-射线粉末衍射图谱在2θ为5.0±0.2°处具有衍射峰;或者在4.8±0.2°处具有衍射峰;或者在15.0±0.2°处具有衍射峰;或者在19.1±0.2°处具有衍射峰;或者在14.3±0.2°处具有衍射峰;或者在10.0±0.2°处具有衍射峰;或者在23.9±0.2°处具有衍射峰;或者在25.1±0.2°处具有衍射峰;或者在30.3±0.2°处具有衍射峰;或者在9.6±0.2°处具有衍射峰;优选包含上述衍射峰中的任意2-5处,或者3-5处,或者3-6处,或者3-8处,或者5-8处,或者6-8处;更优选包含其中任意6处、7处或8处;晶型V的X-射线粉末衍射图谱在2θ为4.7±0.2°处具有衍射峰;或者在18.2±0.2°处具有衍射峰;或者在10.1±0.2°处具有衍射峰;或者在18.8±0.2°处具有衍射峰;或者在15.6±0.2°处具有衍射峰;或者在17.0±0.2°处具有衍射峰;或者在21.8±0.2°处具有衍射峰;或者在14.7±0.2°处具有衍射峰;或者在19.3±0.2°处具有衍射峰;或者在25.8±0.2°处具有衍射峰;优选包含上述衍射峰中的任意2-5处,或者3-5处,或者3-6处,或者3-8处,或者5-8处,或者6-8处;更优选包含其中任意6处、7处或8处。
- 根据权利要求6所述化合物的晶型,其特征在于,晶型I的X-射线粉末衍射图谱 至少包含位于2θ为5.0±0.2°、9.6±0.2°、15.0±0.2°中的一处或多处衍射峰,优选包含其中2处,更优选包含3处;任选的,进一步还可以包含2θ为17.2±0.2°、22.2±0.2°、19.4±0.2°、30.2±0.2°或8.2±0.2°中的至少一处,优选包含其中2处、3处、4处或5处;或者,包含位于2θ为5.0±0.2°、9.6±0.2°、15.0±0.2°、17.2±0.2°、22.2±0.2°和19.4±0.2°处的衍射峰;或者,包含位于2θ为5.0±0.2°、9.6±0.2°、15.0±0.2°、17.2±0.2°、22.2±0.2°和8.2±0.2°处的衍射峰;晶型I的X-射线粉末衍射图谱至少包含位于2θ为5.0±0.2°、8.2±0.2°、9.6±0.2°中的一处或多处衍射峰,优选包含其中2处,更优选包含3处;任选的,进一步还可以包含2θ为12.9±0.2°、15.0±0.2°、17.2±0.2°、15.4±0.2°或16.6±0.2°中的至少一处,优选包含其中2处、3处、4处或5处;或者,包含位于2θ为5.0±0.2°、8.2±0.2°、9.6±0.2°、12.9±0.2°、15.0±0.2°和17.2±0.2°处的衍射峰;或者,包含位于2θ为5.0±0.2°、9.6±0.2°、12.9±0.2°、15.0±0.2°、17.2±0.2°和15.4±0.2°处的衍射峰;晶型II的X-射线粉末衍射图谱至少包含位于2θ为4.8±0.2°、17.7±0.2°、16.6±0.2°中的一处或多处衍射峰,优选包含其中2处,更优选包含3处;任选的,进一步还可以包含2θ为9.4±0.2°、18.4±0.2°、19.1±0.2°、17.0±0.2°或18.6±0.2°中的至少一处,优选包含其中2处、3处、4处或5处;或者,包含位于2θ为4.8±0.2°、17.7±0.2°、16.6±0.2°、9.4±0.2°、18.4±0.2°和19.1±0.2°处的衍射峰;或者,包含位于2θ为4.8±0.2°、17.7±0.2°、16.6±0.2°、9.4±0.2°、18.4±0.2°和17.0±0.2°处的衍射峰;或者,包含位于2θ为4.8±0.2°、17.7±0.2°、16.6±0.2°、9.4±0.2°、18.4±0.2°和18.6±0.2°处的衍射峰;或者,包含位于2θ为4.8±0.2°、17.7±0.2°、9.4±0.2°、18.4±0.2°、19.1±0.2°和17.0±0.2°处的衍射峰;或者,包含位于2θ为4.8±0.2°、16.6±0.2°、9.4±0.2°、18.4±0.2°、19.1±0.2°和17.0±0.2°处的衍射峰;晶型III的X-射线粉末衍射图谱至少包含位于2θ为4.6±0.2°、15.2±0.2°或9.9±0.2°中的一处或多处衍射峰,优选包含其中2处,更优选包含3处;任选的,进一步还可以包含2θ为16.7±0.2°、18.2±0.2°、17.9±0.2°、25.5±0.2°或15.0±0.2°中的至少一处,优选包含其中2处、3处、4处或5处;或者,包含位于2θ为4.6±0.2°、15.2±0.2°、9.9±0.2°、16.7±0.2°、18.2±0.2°和17.9±0.2°处的衍射峰;或者,包含位于2θ为4.6±0.2°、15.2±0.2°、9.9±0.2°、16.7±0.2°、18.2±0.2°和25.5±0.2° 处的衍射峰;或者,包含位于2θ为4.6±0.2°、15.2±0.2°、9.9±0.2°、16.7±0.2°、18.2±0.2°和15.0±0.2°处的衍射峰;或者,包含位于2θ为4.6±0.2°、15.2±0.2°、9.9±0.2°、16.7±0.2°、18.2±0.2°和25.5±0.2°处的衍射峰;或者,包含位于2θ为4.6±0.2°、15.2±0.2°、9.9±0.2°、18.2±0.2°、17.9±0.2°和15.0±0.2°处的衍射峰;晶型IV的X-射线粉末衍射图谱至少包含位于2θ为5.0±0.2°、4.8±0.2°或15.0±0.2°中的一处或多处衍射峰,优选包含其中2处,更优选包含3处;任选的,进一步还可以包含2θ为19.1±0.2°、14.3±0.2°、10.0±0.2°、23.9±0.2°或25.1±0.2°中的至少一处,优选包含其中2处、3处、4处或5处;或者,包含位于2θ为5.0±0.2°、4.8±0.2°、15.0±0.2°、19.1±0.2°、14.3±0.2°和10.0±0.2°处的衍射峰;或者,包含位于2θ为5.0±0.2°、4.8±0.2°、15.0±0.2°、19.1±0.2°、14.3±0.2°和23.9±0.2°处的衍射峰;晶型V的X-射线粉末衍射图谱至少包含位于2θ为4.7±0.2°、18.2±0.2°或10.1±0.2°中的一处或多处衍射峰,优选包含其中2处,更优选包含3处;任选的,进一步还可以包含2θ为18.8±0.2°、15.6±0.2°、17.0±0.2°、21.8±0.2°或14.7±0.2°中的至少一处,优选包含其中2处、3处、4处或5处;或者,包含位于2θ为4.7±0.2°、18.2±0.2°、10.1±0.2°、18.8±0.2、15.6±0.2°和17.0±0.2°处的衍射峰;或者,包含位于2θ为4.7±0.2°、18.2±0.2°、10.1±0.2°、18.8±0.2、15.6±0.2°和21.8±0.2°处的衍射峰;或者,包含位于2θ为4.7±0.2°、18.2±0.2°、10.1±0.2°、18.8±0.2、15.6±0.2°和14.7±0.2°处的衍射峰。
- 根据权利要求6-7任一项所述化合物的晶型,其特征在于,晶型I的X-射线粉末衍射图谱任选还包含位于2θ为10.0±0.2°、25.4±0.2°、26.9±0.2°、13.0±0.2°、12.9±0.2°或20.0±0.2中的一处或多处衍射峰;优选至少包含其中任意2-3处,或者4-5处,或者6处;进一步优选,包含其中任意2处、3处、4处、5处或6处;或者,包含位于2θ为5.0±0.2°、9.6±0.2°、15.0±0.2°、17.2±0.2°、22.2±0.2°、19.4±0.2°、26.9±0.2°和10.0±0.2°处的衍射峰;或者,包含位于2θ为5.0±0.2°、9.6±0.2°、15.0±0.2°、17.2±0.2°、22.2±0.2°、19.4±0.2°、26.9±0.2°和25.4±0.2°处的衍射峰;晶型I的X-射线粉末衍射图谱任选还包含位于2θ为15.4±0.2°、16.6±0.2°、17.7±0.2°、18.5±0.2°、19.3±0.2°或24.0±0.2中的一处或多处衍射峰;优选至少包含其中任意2-3处, 或者4-5处,或者6处;进一步优选,包含其中任意2处、3处、4处、5处或6处;或者,包含位于2θ为5.0±0.2°、8.2±0.2°、9.6±0.2°、15.4±0.2°、16.6±0.2°、17.7±0.2°、18.5±0.2°和19.3±0.2°处的衍射峰;或者,包含位于2θ为5.0±0.2°、8.2±0.2°、9.6±0.2°、16.6±0.2°、17.7±0.2°、18.5±0.2°、19.3±0.2°和24.0±0.2处的衍射峰;晶型II的X-射线粉末衍射图谱任选还包含位于2θ为4.5±0.2°、15.4±0.2°、14.6±0.2°、24.0±0.2°、21.5±0.2°、20.5±0.2°或18.0±0.2中的一处或多处衍射峰;优选至少包含其中任意2-3处,或者4-5处,或者6-7处;进一步优选,包含其中任意2处、3处、4处、5处、6处、7处;或者,包含位于2θ为4.8±0.2°、17.7±0.2°、16.6±0.2°、9.4±0.2°、18.4±0.2°、19.1±0.2°、4.5±0.2°和15.4±0.2°处的衍射峰;或者,包含位于2θ为4.8±0.2°、17.7±0.2°、16.6±0.2°、9.4±0.2°、18.4±0.2°、19.1±0.2°、4.5±0.2°和14.6±0.2°处的衍射峰;晶型III的X-射线粉末衍射图谱任选还包含位于2θ为19.5±0.2°、23.6±0.2°、26.1±0.2°、22.0±0.2°、20.2±0.2°、21.1±0.2°或27.4±0.2中的一处或多出衍射峰;优选至少包含其中任意2-3处,或者4-5处,或者6-7处;进一步优选,包含其中任意2处、3处、4处、5处、6处、7处;或者,包含位于2θ为4.6±0.2°、15.2±0.2°、9.9±0.2°、16.7±0.2°、18.2±0.2°、17.9±0.2°、19.5±0.2°和23.6±0.2°处的衍射峰;或者,包含位于2θ为4.6±0.2°、15.2±0.2°、9.9±0.2°、16.7±0.2°、18.2±0.2°、17.9±0.2°、19.5±0.2°和26.1±0.2°处的衍射峰;晶型IV的X-射线粉末衍射图谱任选还包含位于2θ为30.3±0.2°或9.6±0.2°中的一处或多出衍射峰;优选至少包含其中任意1-2处;或者,包含位于2θ为5.0±0.2°、4.8±0.2°、15.0±0.2°、19.1±0.2°、14.3±0.2°、10.0±0.2°、23.9±0.2°和30.3±0.2°处的衍射峰;或者,包含位于2θ为5.0±0.2°、4.8±0.2°、15.0±0.2°、19.1±0.2°、14.3±0.2°、10.0±0.2°、23.9±0.2°和9.6±0.2°处的衍射峰;晶型V的X-射线粉末衍射图谱任选还包含位于2θ为19.3±0.2°、25.8±0.2°、15.2±0.2°、17.8±0.2°、20.4±0.2°、23.5±0.2°或25.6±0.2°中的一处或多处衍射峰;优选至少包含其中任意2-3处,或者4-5处,或者6-7处;进一步优选,包含其中任意2处、3处、4处、5处、6处、7处;或者,包含位于4.7±0.2°、18.2±0.2°、10.1±0.2°、18.8±0.2°、15.6±0.2°、17.0±0.2°、19.3±0.2°和25.8±0.2°处的衍射峰;或者,包含位于4.7±0.2°、18.2±0.2°、10.1±0.2°、18.8±0.2°、15.6±0.2°、17.0±0.2°、19.3±0.2°和15.2±0.2°处的衍射峰。
- 根据权利要求6所述化合物的晶型,其特征在于,晶型I的X-射线粉末衍射图谱包含位于2θ为5.0±0.2°、9.6±0.2°、15.0±0.2°、17.2±0.2°、22.2±0.2°、19.4±0.2°、30.2±0.2°、25.1±0.2°、10.0±0.2°、25.4±0.2°、26.9±0.2°、13.0±0.2°、12.9±0.2°或20.0±0.2中的一处或多处衍射峰;优选的,包含其中任选的4处、5处、6处、8处或10处有衍射峰;晶型I的X-射线粉末衍射图谱在2θ为以下位置处有衍射峰:9.6±0.2°、15.0±0.2°和17.2±0.2°处;或者,5.0±0.2°、9.6±0.2°、15.0±0.2°和17.2±0.2°处;或者,5.0±0.2°、9.6±0.2°、15.0±0.2°和22.2±0.2°处;或者,5.0±0.2°、9.6±0.2°、15.0±0.2°、17.2±0.2°、22.2±0.2°和25.1±0.2°处;晶型I的X-射线粉末衍射图谱包含位于2θ为5.0±0.2°、8.2±0.2°、9.6±0.2°、12.9±0.2°、15.0±0.2°、17.2±0.2°、15.4±0.2°、16.6±0.2°、17.7±0.2°、18.5±0.2°、19.3±0.2°或24.0±0.2中的一处或多处衍射峰;优选的,包含其中任选的4处、5处、6处、8处或10处有衍射峰;晶型I的X-射线粉末衍射图谱在2θ为以下位置处有衍射峰:8.2±0.2°、9.6±0.2°、12.9±0.2°、15.0±0.2°、17.2±0.2°、15.4±0.2°、16.6±0.2°和17.7±0.2°处;或者,5.0±0.2°、8.2±0.2°、9.6±0.2°、12.9±0.2°、15.0±0.2°、17.2±0.2°、15.4±0.2°、16.6±0.2°、17.7±0.2°和18.5±0.2°处;或者,8.2±0.2°、9.6±0.2°、12.9±0.2°、15.0±0.2°、17.2±0.2°、15.4±0.2°、16.6±0.2°、17.7±0.2°、18.5±0.2°和19.3±0.2°处;晶型II的X-射线粉末衍射图谱包含位于2θ为4.8±0.2°、17.7±0.2°、16.6±0.2°、9.4±0.2°、18.4±0.2°、19.1±0.2°、17.0±0.2°、18.6±0.2°、4.5±0.2°、15.4±0.2°、14.6±0.2°、24.0±0.2°、21.5±0.2°、20.5±0.2°或18.0±0.2中的一处或多处衍射峰;优选的,包含其中任选的4处、5处、6处、8处或10处有衍射峰;晶型II的X-射线粉末衍射图谱在2θ为以下位置处有衍射峰:4.8±0.2°、17.7±0.2°、16.6±0.2°和9.4±0.2°处;或者,4.8±0.2°、17.7±0.2°、16.6±0.2°和18.4±0.2°处;或者,4.8±0.2°、17.7±0.2°、16.6±0.2°、9.4±0.2°、18.4±0.2°和20.5±0.2°处;或者,4.8±0.2°、17.7±0.2°、16.6±0.2°、9.4±0.2°、18.4±0.2°、19.1±0.2°、17.0±0.2°和18.6±0.2°处;或者,4.8±0.2°、17.7±0.2°、16.6±0.2°、9.4±0.2°、18.4±0.2°、19.1±0.2°、17.0±0.2°、18.6±0.2°、4.5±0.2°、14.6±0.2°处;晶型III的X-射线粉末衍射图谱包含位于2θ为2θ为4.6±0.2°、15.2±0.2°、9.9±0.2°、16.7±0.2°、18.2±0.2°、17.9±0.2°、25.5±0.2°、15.0±0.2°、19.5±0.2°、23.6±0.2°、26.1±0.2°、22.0±0.2°、20.2±0.2°、21.1±0.2°或27.4±0.2中的一处或多处衍射峰;优选的,包含其中任选的4处、5处、6处、8处或10处有衍射峰;晶型III的X-射线粉末衍射图谱在2θ为以下位置处有衍射峰:4.6±0.2°、15.2±0.2°、9.9±0.2°和16.7±0.2°处;或者,4.6±0.2°、15.2±0.2°、9.9±0.2°和18.2±0.2°处;或者,4.6±0.2°、15.2±0.2°、16.7±0.2°和18.2±0.2°处;或者,4.6±0.2°、15.2±0.2°、9.9±0.2°、16.7±0.2°、18.2±0.2°和17.9±0.2°处;或者,4.6±0.2°、15.2±0.2°、9.9±0.2°、16.7±0.2°、18.2±0.2°、17.9±0.2°、26.1±0.2°和22.0±0.2°处;或者,4.6±0.2°、15.2±0.2°、9.9±0.2°、16.7±0.2°、18.2±0.2°、17.9±0.2°、25.5±0.2°、15.0±0.2°、19.5±0.2°和23.6±0.2°处;晶型IV的X-射线粉末衍射图谱包含位于2θ为2θ为5.0±0.2°、4.8±0.2°、15.0±0.2°、19.1±0.2°、14.3±0.2°、10.0±0.2°、23.9±0.2°、25.1±0.2°、30.3±0.2°或9.6±0.2°中的一处或多处衍射峰;优选的,包含其中任选的4处、5处、6处、8处或10处有衍射峰;晶型IV的X-射线粉末衍射图谱在2θ为以下位置处有衍射峰:包含位于2θ为5.0±0.2°、4.8±0.2°、15.0±0.2°和19.1±0.2°处的衍射峰;或者,5.0±0.2°、4.8±0.2°、15.0±0.2°和14.3±0.2°处;或者,5.0±0.2°、4.8±0.2°、15.0±0.2°、19.1±0.2°、23.9±0.2°和25.1±0.2°处;或者,5.0±0.2°、4.8±0.2°、15.0±0.2°、19.1±0.2°、14.3±0.2°、10.0±0.2°、23.9±0.2°和25.1±0.2°处;或者,5.0±0.2°、4.8±0.2°、15.0±0.2°、19.1±0.2°、14.3±0.2°、10.0±0.2°、23.9±0.2°、25.1±0.2°和30.3±0.2°处;或者,5.0±0.2°、4.8±0.2°、15.0±0.2°、19.1±0.2°、14.3±0.2°、10.0±0.2°、23.9±0.2°、25.1±0.2°、30.3±0.2°和9.6±0.2°处;晶型V的X-射线粉末衍射图谱包含位于2θ为4.7±0.2°、18.2±0.2°、10.1±0.2°、18.8±0.2°、15.6±0.2°、17.0±0.2°、21.8±0.2°、14.7±0.2°、19.3±0.2°、25.8±0.2°、15.2±0.2°、17.8±0.2°、20.4±0.2°、23.5±0.2°或25.6±0.2°中的一处或多处衍射峰;优选的,包含其中任选的4处、5处、6处、8处或10处有衍射峰;晶型V的X-射线粉末衍射图谱在2θ为以下位置处有衍射峰:4.7±0.2°、18.2±0.2°、10.1±0.2°和18.8±0.2处;或者,4.7±0.2°、10.1±0.2°、18.8±0.2°、15.6±0.2°、17.0±0.2°和21.8±0.2°处;或者,4.7±0.2°、18.2±0.2°、10.1±0.2°、18.8±0.2°、15.6±0.2°、17.0±0.2°、21.8±0.2°和14.7±0.2°处;或者,4.7±0.2°、18.2±0.2°、10.1±0.2°、18.8±0.2°、15.6±0.2°、17.0±0.2°、21.8±0.2°、14.7±0.2°、19.3±0.2°和15.2±0.2°处。
- 根据权利要求1-9中任一项所述化合物的晶型,其特征在于,晶型I的X-射线粉末衍射图谱如图1所示;晶型II的X-射线粉末衍射图谱如图4所示;晶型III的X-射线 粉末衍射图谱如图7所示;晶型IV的X-射线粉末衍射图谱如图10所示;晶型V的X-射线粉末衍射图谱如图13所示。
- 根据权利要求1-9中任一项所述化合物的晶型,其特征在于,晶型I、晶型II、晶型III、晶型IV、晶型V的X-射线粉末衍射图谱中相对峰强度为前十强的衍射峰位置分别与图1、图4、图7、图10和图13对应位置衍射峰的2θ误差为±0.2°~±0.5°,优选±0.2°~±0.3°,最优选±0.2°。
- 根据权利要求1-9中任一项所述化合物的晶型,其特征在于,晶型I具有如图2所示的DSC图谱;或者具有如图3所示的TGA图谱;晶型II具有如图5所示的DSC图谱;或者具有如图6所示的TGA图谱;晶型III具有如图8所示的DSC图谱;或者具有如图9所示的TGA图谱;晶型IV具有如图11所示的DSC图谱;或者具有如图12所示的TGA图谱;晶型V具有如图14所示的DSC图谱;或者具有如图15所示的TGA图谱。
- 根据权利要求1-12中任一项所述化合物的晶型,其特征在于,晶型为含溶剂或不含溶剂的晶型,其中溶剂选自水、甲醇、丙酮、乙酸乙酯、乙腈、乙醇、88%丙酮、四氢呋喃、2-甲基-四氢呋喃、二氯甲烷、1,4-二氧六环、苯、甲苯、异丙醇、正丁醇、异丁醇、N,N-二甲基甲酰胺、N,N-二甲基乙酰胺、N-甲基吡咯烷酮、二甲基亚砜、正丙醇、叔丁醇、2-丁酮、3-戊酮、正庚烷、庚烷、甲酸乙酯、醋酸异丙酯、环己烷、甲基叔丁基醚或异丙醚中的一种或多种,优选的,晶型为无水晶型。
- 根据权利要求13所述化合物的晶型,其特征在于,溶剂的个数为0~3,优选0、0.2、0.5、1、1.5、2、2.5或3,更优选0、0.5、1、2或3。
- 一种制备权利要求1-14中任一项所述化合物的晶型的方法,具体包括如下步骤:1)称取适量的自由碱,用不良溶剂混悬,悬浮密度优选为50~200mg/mL;2)以上所得混悬液振摇,温度优选0~50℃;3)将以上混悬液快速离心,去除上清液,剩余固体干燥得到目标产物;其中:不良性溶剂选自甲醇、丙酮、乙酸乙酯、四氢呋喃、乙腈、乙醇、88%丙酮、2-甲基-四氢呋喃、二氯甲烷、1,4-二氧六环、甲基叔丁基醚、正庚烷、苯、甲苯、氯苯、异丙醇、正丁醇、异丁醇、N,N-二甲基甲酰胺、N,N-二甲基乙酰胺、二甲基亚砜、正丙醇、甲酸乙酯、醋酸异丙酯、叔丁醇、2-丁酮或3-戊酮的一种或多种;优选乙腈、丙酮、乙酸乙酯、甲醇或乙醇的一种或多种。
- 一种制备权利要求1-14中任一项所述化合物的晶型的方法,具体包括如下步骤:1)称取适量的自由碱,用良溶剂溶解;2)任选地,向以上所得溶液中加入不良溶剂;3)搅拌至固体析出,析晶温度选自0~50℃;4)任选地,将以上混悬液快速离心;5)去除上清液,剩余固体干燥得到目标产物;其中:良性溶剂选自甲醇、丙酮、乙酸乙酯、四氢呋喃、乙腈、乙醇、88%丙酮、2-甲基-四氢呋喃、二氯甲烷、1,4-二氧六环、苯、甲苯、氯苯、异丙醇、正丁醇、异丁醇、N,N-二甲基甲酰胺、N,N-二甲基乙酰胺、二甲基亚砜、正丙醇、甲酸乙酯、醋酸异丙酯、叔丁醇、2-丁酮或3-戊酮的一种或多种;优选二氯甲烷、四氢呋喃、2-甲基-四氢呋喃、1,4-二氧六环、二甲基亚砜、乙腈或2-丁酮中的一种或多种;不良溶剂选自甲醇、乙醇、乙酸乙酯、丙酮、异丙醇、甲苯、正庚烷、水、醋酸异丙酯、环己烷、甲基叔丁基醚或异丙醚的一种或多种;优选水、正庚烷、环己烷或甲基叔丁基醚中的一种或多种。
- 一种药物组合物,其包括治疗有效剂量的权利要求1~14中所示的各通式化合物的晶型以及一种或多种药学上可接受的载体赋形剂。
- 根据权利要求1~14中任一项所述化合物的晶型,或权利要求17所述的药物组合物在制备RET抑制剂药物中的应用。
- 根据权利要求1~14中任一项所述化合物的晶型,或权利要求17所述的药物组合物在制备用于治疗和/或预防肿瘤药物中的应用,优选的,肿瘤选自非小细胞肺癌、纤维肉瘤、胰腺肿瘤、甲状腺髓样癌、甲状腺乳头状肿瘤、软组织肉瘤、高度实性肿瘤、乳腺肿瘤和结肠肿瘤。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020237018439A KR20230107271A (ko) | 2020-11-13 | 2021-11-15 | 이환식 유도체를 포함하는 억제제 유리염기의 결정형, 이의 제조방법 및 용도 |
CN202180076060.XA CN116528859A (zh) | 2020-11-13 | 2021-11-15 | 含二并环类衍生物抑制剂自由碱的晶型及其制备方法和应用 |
CA3198559A CA3198559A1 (en) | 2020-11-13 | 2021-11-15 | Crystal form of free base of inhibitor containing bicyclic ring derivative and preparation method and application of crystal form |
AU2021377952A AU2021377952A1 (en) | 2020-11-13 | 2021-11-15 | Crystal form of free base of inhibitor containing bicyclic ring derivative and preparation method and application of crystal form |
JP2023528719A JP2023550069A (ja) | 2020-11-13 | 2021-11-15 | 二環系誘導体を含む阻害剤の遊離塩基の結晶及びその製造方法と使用 |
US18/036,730 US20230406865A1 (en) | 2020-11-13 | 2021-11-15 | Crystal form of free base of inhibitor containing bicyclic ring derivative and preparation method and application of crystal form |
EP21891258.2A EP4245757A1 (en) | 2020-11-13 | 2021-11-15 | Crystal form of free base of inhibitor containing bicyclic ring derivative and preparation method and application of crystal form |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011271725 | 2020-11-13 | ||
CN202011271725.6 | 2020-11-13 | ||
CN202111333586.X | 2021-11-11 | ||
CN202111333586 | 2021-11-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022100738A1 true WO2022100738A1 (zh) | 2022-05-19 |
Family
ID=81600792
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/130725 WO2022100738A1 (zh) | 2020-11-13 | 2021-11-15 | 含二并环类衍生物抑制剂自由碱的晶型及其制备方法和应用 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20230406865A1 (zh) |
EP (1) | EP4245757A1 (zh) |
JP (1) | JP2023550069A (zh) |
KR (1) | KR20230107271A (zh) |
CN (1) | CN116528859A (zh) |
AU (1) | AU2021377952A1 (zh) |
CA (1) | CA3198559A1 (zh) |
TW (1) | TW202220989A (zh) |
WO (1) | WO2022100738A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024027690A1 (zh) * | 2022-08-01 | 2024-02-08 | 江苏豪森药业集团有限公司 | 一种二并环类抑制剂的中间体及其制备方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108349969A (zh) * | 2015-07-16 | 2018-07-31 | 阵列生物制药公司 | 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡啶化合物 |
CN110177786A (zh) * | 2016-10-10 | 2019-08-27 | 阿雷生物药品公司 | 经取代的吡唑并[1,5-a]吡啶化合物作为ret激酶抑制剂 |
CN110382494A (zh) * | 2016-10-10 | 2019-10-25 | 阿雷生物药品公司 | 经取代的吡唑并[1,5-a]吡啶化合物作为ret激酶抑制剂 |
CN111278822A (zh) * | 2017-10-10 | 2020-06-12 | 阿雷生物药品公司 | 结晶形式 |
CN111635400A (zh) * | 2019-03-02 | 2020-09-08 | 察略盛医药科技(上海)有限公司 | 吡唑并[1,5-a]吡啶类衍生物、及其制备方法和用途 |
WO2020228756A1 (zh) * | 2019-05-14 | 2020-11-19 | 上海翰森生物医药科技有限公司 | 含二并环类衍生物抑制剂、其制备方法和应用 |
-
2021
- 2021-11-15 TW TW110142459A patent/TW202220989A/zh unknown
- 2021-11-15 WO PCT/CN2021/130725 patent/WO2022100738A1/zh active Application Filing
- 2021-11-15 EP EP21891258.2A patent/EP4245757A1/en active Pending
- 2021-11-15 AU AU2021377952A patent/AU2021377952A1/en active Pending
- 2021-11-15 CN CN202180076060.XA patent/CN116528859A/zh active Pending
- 2021-11-15 CA CA3198559A patent/CA3198559A1/en active Pending
- 2021-11-15 US US18/036,730 patent/US20230406865A1/en active Pending
- 2021-11-15 JP JP2023528719A patent/JP2023550069A/ja active Pending
- 2021-11-15 KR KR1020237018439A patent/KR20230107271A/ko unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108349969A (zh) * | 2015-07-16 | 2018-07-31 | 阵列生物制药公司 | 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡啶化合物 |
CN110177786A (zh) * | 2016-10-10 | 2019-08-27 | 阿雷生物药品公司 | 经取代的吡唑并[1,5-a]吡啶化合物作为ret激酶抑制剂 |
CN110382494A (zh) * | 2016-10-10 | 2019-10-25 | 阿雷生物药品公司 | 经取代的吡唑并[1,5-a]吡啶化合物作为ret激酶抑制剂 |
CN111278822A (zh) * | 2017-10-10 | 2020-06-12 | 阿雷生物药品公司 | 结晶形式 |
CN111635400A (zh) * | 2019-03-02 | 2020-09-08 | 察略盛医药科技(上海)有限公司 | 吡唑并[1,5-a]吡啶类衍生物、及其制备方法和用途 |
WO2020228756A1 (zh) * | 2019-05-14 | 2020-11-19 | 上海翰森生物医药科技有限公司 | 含二并环类衍生物抑制剂、其制备方法和应用 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024027690A1 (zh) * | 2022-08-01 | 2024-02-08 | 江苏豪森药业集团有限公司 | 一种二并环类抑制剂的中间体及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CA3198559A1 (en) | 2022-05-19 |
TW202220989A (zh) | 2022-06-01 |
CN116528859A (zh) | 2023-08-01 |
US20230406865A1 (en) | 2023-12-21 |
AU2021377952A1 (en) | 2023-06-29 |
JP2023550069A (ja) | 2023-11-30 |
EP4245757A1 (en) | 2023-09-20 |
KR20230107271A (ko) | 2023-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113396147B (zh) | 芳香杂环类衍生物调节剂、其制备方法和应用 | |
WO2020239077A1 (zh) | 含氮杂环类衍生物调节剂、其制备方法和应用 | |
CN112368283B (zh) | 含二并环类衍生物抑制剂、其制备方法和应用 | |
CN112552294B (zh) | 含哌嗪杂环类衍生物抑制剂、其制备方法和应用 | |
WO2020253860A1 (zh) | 芳基磷氧化物类衍生物抑制剂、其制备方法和应用 | |
WO2020233669A1 (zh) | 含吲哚类衍生物抑制剂、其制备方法和应用 | |
WO2023025320A1 (zh) | 含氮杂环类衍生物抑制剂、其制备方法和应用 | |
WO2021197452A1 (zh) | 含氮杂芳类衍生物自由碱的晶型 | |
CN113493440A (zh) | 含氮杂芳类衍生物的盐及其晶型 | |
WO2022100738A1 (zh) | 含二并环类衍生物抑制剂自由碱的晶型及其制备方法和应用 | |
WO2022111644A1 (zh) | 含氮杂环类衍生物的盐、晶型及其制备方法和应用 | |
WO2023011505A1 (zh) | 嘧啶或吡啶衍生物及其制备方法和在药学上的应用 | |
CN114478586A (zh) | 一种含二并环类衍生物抑制剂盐或晶型及其制备方法和应用 | |
WO2022033455A1 (zh) | 具有egfr抑制活性的三嗪衍生物及其制备方法和应用 | |
CN115073426A (zh) | 嘧啶杂环化合物及其制备方法和应用 | |
RU2820948C2 (ru) | Ингибитор, содержащий бициклическое производное, способ его получения и его применение | |
WO2024022286A1 (zh) | 大环egfr抑制剂及其制备方法和药学上的应用 | |
WO2018205938A1 (zh) | Parp抑制剂、其药物组合物、制备方法和应用 | |
CN115803325B (zh) | 一种egfr抑制剂及其制备方法和应用 | |
WO2022127807A1 (zh) | 一种芳基磷氧化物类衍生物自由碱的晶型及其制备方法和应用 | |
WO2022161447A1 (zh) | 二甲酰胺类化合物、其制备方法及其在医药上的应用 | |
WO2022116995A1 (zh) | 2,3-二氢-1H-吡咯并[3,2-b]吡啶衍生物、其制备方法和应用 | |
TW202416988A (zh) | 含氮雜環的多環化合物的游離鹼晶型及其製備方法 | |
TW202136259A (zh) | 聯苯類衍生物抑制劑及其製備方法和應用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21891258 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202180076060.X Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 3198559 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18036730 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023528719 Country of ref document: JP |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023009149 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 20237018439 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021891258 Country of ref document: EP Effective date: 20230613 |
|
ENP | Entry into the national phase |
Ref document number: 2021377952 Country of ref document: AU Date of ref document: 20211115 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112023009149 Country of ref document: BR Kind code of ref document: A2 Effective date: 20230512 |